EP1036075B1 - Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties - Google Patents

Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties Download PDF

Info

Publication number
EP1036075B1
EP1036075B1 EP98918108A EP98918108A EP1036075B1 EP 1036075 B1 EP1036075 B1 EP 1036075B1 EP 98918108 A EP98918108 A EP 98918108A EP 98918108 A EP98918108 A EP 98918108A EP 1036075 B1 EP1036075 B1 EP 1036075B1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
group
oxo
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP98918108A
Other languages
German (de)
French (fr)
Other versions
EP1036075A1 (en
Inventor
Vidya Bhushan Lohray
Braj Bhushan Lohray
Rao Bheema Paraselli
Rajagopalan Ramanujam
Ranjan Chakrabarti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/982,911 external-priority patent/US6313113B1/en
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of EP1036075A1 publication Critical patent/EP1036075A1/en
Application granted granted Critical
Publication of EP1036075B1 publication Critical patent/EP1036075B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/201,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel antidiabetic compounds, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
  • This invention particularly relates to novel azolidinediones of the general formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
  • the present invention also relates to a process for the preparation of the above said novel azolidinedione compounds, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, and pharmaceutically acceptable solvates; and pharmaceutical compositions containing them.
  • This invention also relates to novel intermediates, processes for preparing the intermediates and processes for using the intermediates.
  • the azolidinediones of the general formula (I) defined above of the present invention are useful for the treatment and / or prophylaxis of hyperlipidemia, hypercholesterolemia, hyperglycemia, osteoporosis, obesity, glucose intolerance, insulin resistance and also diseases or conditions in which insulin resistance is the underlying pathophysiological mechanism. Examples of these diseases and conditions are type II diabetes, impaired glucose tolerance, dyslipidaemia, hypertension, coronary heart disease and other cardiovascular disorders including atherosclerosis.
  • the azolidinediones of formula (I) are useful for the treatment of insulin resistance associated with obesity and psoriasis.
  • the azolidinediones of the formula (I) can also be used to treat diabetic complications and can be used for treatment and / or prophylaxis of other diseases and conditions such as polycystic ovarian syndrome (PCOS), certain renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal diseases and microalbuminuria as well as certain eating disorders, as aldose reductase inhibitors and for improving cognitive functions in dementia.
  • PCOS polycystic ovarian syndrome
  • certain renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal diseases and microalbuminuria as well as certain eating disorders, as aldose reductase inhibitors and for improving cognitive functions in dementia.
  • Insulin resistance is the diminished ability of insulin to exert its biological action across a broad range of concentrations.
  • the body secretes abnormally high amounts of insulin to compensate for this defect; failing which, the plasma glucose concentration inevitably rises and develops into diabetes.
  • diabetes mellitus is a common problem and is associated with a variety of abnormalities including obesity, hypertension, hyperlipidemia (J. Clin. Invest., (1985) 75 : 809 - 817; N. Engl. J. Med. (1987) 317 : 350 - 357 ; J. Clin. Endocrinol. Metab., (1988) 66 : 580 - 583; J. Clin.
  • a number of molecular defects have been associated with insulin resistance. These include reduced expression of insulin receptors on the plasma membrane of insulin responsive cells and alterations in the signal transduction pathways that become activated after insulin binds to its receptor including glucose transport and glycogen synthesis.
  • R 1 represents an alkyl group, alkoxy group, halogen atom, halogenoalkyl group, amino group, hydroxy group, benzyloxy group which may have a substituent, cyano group, carbamoyl group, acyl group, nitro group, carboxy group, or sulfonamide group
  • R 2 and R 3 may be the same or different and each individually represents a hydrogen atom or an alkyl group, or R 2 and R 3 indicate in combination an alkylene group having 2-7 carbon atoms
  • R 4 and R 5 may be the same or different and each individually represents a hydrogen atom or an alkyl group
  • X denotes O, S, or N-R 6 (wherein R 6 represents a hydrogen atom, an alkyl group, or an aryl group or pyridyl group which may have a substituent);
  • m is an integer from 0 to 4; and n is an integer from 1 to 3 have been disclosed in EP 0 787 727 Al.
  • NIDDM non-insulin-dependent-diabetes mellitus
  • the main objective of the present invention is therefore, to provide novel azolidinediones, their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them and mixtures thereof.
  • Another objective of the present invention is to provide novel azolidinedione compounds, their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them and mixtures thereof having enhanced activities, no toxic effect or reduced toxic effect.
  • Yet another objective of the present invention is to provide a process for the preparation of novel azolidinediones of the formula (I) as defined above, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates.
  • Still another objective of the present invention is to provide pharmaceutical compositions containing compounds of the general formula (I), their tautomers, their stereoisomers, their polymorphs, their salts, solvates or mixtures thereof in combination with suitable carriers, solvents, diluents, excipients and other media normally employed in preparing such compositions.
  • Yet another objective of the present invention is to provide novel intermediates of the formula (III) where G represents - CHO, -NH 2 or -CH 2 CH(J)-COOR, where J represents halogen atom such as chlorine, bromine or iodine and R represents H or lower alkyl group such as (C 1 - C 6 ) alkyl group, preferably a (C 1 - C 3 ) alkyl group such as methyl, ethyl, or propyl; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, W, n and Ar are defined as in formula (I).
  • Still another objective of the present invention is to provide a process for the preparation of the novel intermediates of the formula (III) where G represents -CHO, -NH 2 or -CH 2 CH(J)-COOR, where J represents halogen atom such as chlorine, bromine or iodine and R represents H or lower alkyl group such as (C 1 - C 6 ) alkyl group, preferably a (C 1 - C 3 ) alkyl group such as methyl, ethyl, or propyl; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, W, n and Ar are defined as in formula (I).
  • Azolidinediones of the present invention have the general formula (I)
  • X represents O or S
  • the groups R 1 , R 2 , R 3 , R 4 may be same or different and represent hydrogen, halogen, hydroxy, cyano, nitro; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkyloxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, aryloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylamino, arylamino, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, acyl, acylamino, aryloxycarbonylamino, aralkoxycarbonylamino, alkoxycarbonylamino, carboxylic acid or its optionally substituted amides,
  • Suitable groups represented by R 1 , R 2 , R 3 , R 4 may be selected from hydrogen, halogen atom such as fluorine, chlorine, bromine, or iodine; hydroxy, cyano, nitro; substituted or unsubstituted (C 1 -C 12 )alkyl group, especially, linear or branched (C 1 -C 6 )alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, t-butyl, n-pentyl, isopentyl, hexyl and the like: cycloalkyl group such as cyclopropyl.
  • cycloalkyl group may be substituted: cycloalkyloxy group such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like, cycloalkyloxy group may be substituted; aryl group such as phenyl or naphthyl, the aryl group may be substituted; aralkyl such as benzyl or phenethyl, the aralkyl group may be substituted: heteroaryl group such as pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, tetrazolyl, benzopyranyl, benzofuranyl and the like, the heteroaryl group may be substituted; heteroaralkyl wherein the heteroaryl moiety
  • the heterocyclyl group may be substituted; aryloxy such as phenoxy, naphthyloxy, the aryloxy group may be substituted; alkoxycarbonyl such as methoxycarbonyl or ethoxycarbonyl, the alkoxycarbonyl group may be substituted; aryloxycarbonyl group such as optionally substituted phenoxycarbonyl or naphthyloxycarbonyl; substituted or unsubstituted aralkoxycarbonyl wherein the aryl moiety is phenyl or naphthyl, such as benzyloxycarbonyl, phenethyloxycarbonyl.
  • C 1 - C 6 alkylamino arylamino group such as HNC 6 H 5 ; -NCH 3 C 6 H 5 , -NHC 6 H 4 -CH 3 , -NHC 6 H 4 -halo and the like, amino group: amino(C 1 -C 6 )alkyl: hydroxy(C 1 -C 6 )alkyl; (C 1 -C 6 )alkoxy; alkoxyalkyl such as methoxymethyl, ethoxymethyl, methoxyethyl and the like; thio(C 1 -C 6 )alkyl; (C 1 -C 6 )alkylthio; acyl group such as acetyl, propionyl or benzoyl, the acyl group may be substituted; acylamino groups such as NHCOCH 3 , NHCOC 2 H 5 , NHCOC 3 H 7
  • alkoxy, alkylamino, arylamino, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, acylamino, aryloxycarbonylamino, aralkoxycarbonylamino, and alkoxycarbonylamino groups may also be substituted.
  • the substituents may be selected from halogen, hydroxy, cyano, nitro, alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, acyloxy, hydroxyalkyl, amino, acylamino, arylamino, aminoalkyl, aryloxy, alkoxycarbonyl, alkylamino such as NHCH 3 , N(CH 3 ) 2 , NCH 3 (C 2 H 5 ), NHC 2 H 5 and the like; alkoxyalkyl such as methoxymethyl, ethoxymethyl, methoxyethyl and the like; alkylthio, thioalkyl groups, carboxylic acid or its optionally substituted amides, or sulfonic acid or its optionally substituted amides.
  • R 1 - R 4 represent hydrogen; halogen atom such as fluorine, chlorine, bromine; alkyl group such as methyl, ethyl, isopropyl, n-propyl, n-butyl; and the like which may be halogenated; optionally halogenated groups selected from cycloalkyl group such as cyclopropyl; aryl group such as phenyl; aralkyl group such as benzyl; (C 1 -C 3 )alkoxy, aryloxy group such as benzyloxy, hydroxy group, acyl or acyloxy groups.
  • halogen atom such as fluorine, chlorine, bromine
  • alkyl group such as methyl, ethyl, isopropyl, n-propyl, n-butyl
  • optionally halogenated groups selected from cycloalkyl group such as cyclopropyl; aryl group such as phenyl; aral
  • Suitable R 6 and R 9 are selected from hydrogen, substituted or unsubstituted (C 1 -C 12 )alkyl group, especially, linear or branched (C 1 -C 6 )alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, t-butyl, n-pentyl, isopentyl, hexyl and the like; substituted or unsubstituted cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like; aryl group such as phenyl or naphthyl, the aryl group may be substituted; aralkyl group such as benzyl or phenethyl, the aralkyl group may be substituted; heteroaryl group such as pyridyl, thienyl, furyl
  • the preferred substituents are halogen such as fluorine, chlorine; hydroxy, acyl. acyloxy, and amino groups.
  • acyl and acyloxy groups are as defined above.
  • Suitable R 5 may be hydrogen, halogen, hydroxy or optionally substituted (C 1 -C 6 )alkyl group which may be linear or branched, aryl. heteroaryl, (C 1 -C 6 )alkoxy, aralkyl, arakoxy, or acyl groups.
  • R 5 may be substituted by hydroxy. halogen. linear or branched (C 1 -C 6 ) alkyl group, acyl or acyloxy group.
  • n is an integer ranging from 1 - 4. It is preferred that n be I or 2.
  • the group represented by Ar be substituted or unsubstituted groups selected from divalent phenylene, naphthylene, pyridyl, quinolinyl, benzofuryl, dihydrobenzofuryl, benzopyranyl, indolyl, indolinyl, azaindolyl, azaindolinyl, pyrazolyl, benzothiazolyl, benzoxazolyl and the like.
  • the substituents on the group represented by Ar may be selected from linear or branched (C 1 -C 6 )alkyl, (C 1 -C 3 )alkoxy, halogen, acyl, amino, acylamino, thio or carboxylic or sulfonic acids and their derivatives.
  • Ar represents substituted or unsubstituted divalent phenylene, naphthylene, benzofuryl, indolyl, indolinyl, quinolinyl, azaindolyl, azaindolinyl, benzothiazolyl or benzoxazolyl.
  • Ar represents divalent phenylene or naphthylene, which may be optionally substituted by methyl, halomethyl, methoxy or halomethoxy groups.
  • Suitable R 7 includes hydrogen, hydroxy, lower alkyl group such as (C 1 -C 6 )alkyl such as methyl, ethyl or propyl; substituted or unsubstituted aralkyl group such as benzyl, phenethyl CH 2 C 6 H 4 -Halo, CH 2 C 6 H 4 -OCH 3 , CH 2 C 6 H 4 CH 3 , CH 2 CH 2 C 6 H 4 CH 3 and the like; halogen atom such as fluorine, chlorine bromine or iodine: or R 7 together with R 8 represents a bond.
  • lower alkyl group such as (C 1 -C 6 )alkyl such as methyl, ethyl or propyl
  • substituted or unsubstituted aralkyl group such as benzyl, phenethyl CH 2 C 6 H 4 -Halo, CH 2 C 6 H 4 -OCH 3 , CH 2 C 6 H 4 CH 3 ,
  • R 7 represents hydrogen or a bond together with R 8 .
  • Suitable R 8 represents hydrogen, hydroxy, lower alkyl group such as (C 1 -C 6 )alkyl such as methyl, ethyl or propyl; substituted or unsubstituted aralkyl group such as benzyl, phenethyl, CH 2 C 6 H 4 -Halo, CH 2 C 6 H 4 -OCH 3 , CH 2 C 6 H 4 CH 3 , CH 2 CH 2 C 6 H 4 CH 3 and the like; halogen atom such as fluorine, chlorine, bromine or odine; or together with R 7 forms a bond.
  • C 1 -C 6 )alkyl such as methyl, ethyl or propyl
  • substituted or unsubstituted aralkyl group such as benzyl, phenethyl, CH 2 C 6 H 4 -Halo, CH 2 C 6 H 4 -OCH 3 , CH 2 C 6 H 4 CH 3 , CH 2 CH 2 C 6 H 4
  • R 7 or R 8 is lower alkyl
  • the lower alkyl may be substituted by groups such as halogen, methyl or oxo group.
  • Suitable B group includes a hetero atom selected from O or S.
  • Suitable ring structure comprising B include 2.4-dioxooxazolidinyl, 2.4-dioxothiazolidinyl groups.
  • the ring structure comprising B is a 2,4-dioxothiazolidinyl group.
  • R 1 - R 9 The groups represented by R 1 - R 9 and any substituents on these groups may be defined as disclosed anywhere in the specification.
  • Pharmaceutically acceptable salts forming part of this invention include salts of the azolidinedione moiety such as alkali metal salts like Li, Na. and K salts. alkaline earth metal salts like Ca and Mg salts, salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline and the like, ammonium or substituted ammonium salts, salts of carboxy group wherever appropriate, such as aluminum, alkali metal salts; alkaline earth metal salts, ammonium or substituted ammonium salts.
  • alkali metal salts like Li, Na. and K salts.
  • alkaline earth metal salts like Ca and Mg salts
  • salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline and the like
  • ammonium or substituted ammonium salts salts of carboxy group wherever appropriate, such as aluminum, alkali metal salts; alkaline earth metal salts, ammoni
  • Salts may include acid addition salts which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulfonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like.
  • Pharmaceutically acceptable solvates may be hydrates or comprising other solvents of crystallization such as alcohols.
  • Particularly useful compounds according to the present invention include :
  • the invention also includes an intermediate of formula (III) wherein X represents O or S; the groups R 1 , R 2 , R 3 , R 4 may be same or different and represent hydrogen, halogen, hydroxy, cyano, nitro; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkyloxy, aryl, aralkyl, heteroaryl. heteroaralkyl, heterocyclyl, aryloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylamino, arylamino, amino.
  • formula (III) wherein X represents O or S; the groups R 1 , R 2 , R 3 , R 4 may be same or different and represent hydrogen, halogen, hydroxy, cyano, nitro; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkyloxy, aryl, aralkyl, heteroaryl
  • R 6 and R 9 may be same or different and represent hydrogen or optionally substituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl. acyl, hydroxyalkyl.
  • R 5 represents hydrogen, hydroxy or halogen or optionally substituted alkyl, aryl, heteroaryl, acyl, alkoxy, aralkyl, or aralkoxy;
  • n is an integer ranging from 1 - 4;
  • Ar represents an optionally substituted divalent aromatic or heterocyclic group;
  • G represents CHO, -NH 2 or -CH 2 CH(J)-COOR, where J represents a halogen atom and R represents H or lower alkyl group.
  • G represents -CHO group which comprises, reacting a compound of the general formula (IV) wherein, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, W, n, and Ar are as defined earlier, with a compound of general formula (V) L 1 ⁇ Ar ⁇ G where L 1 is a halogen atom such as fluorine or chlorine, G is a CHO group and Ar is as defined earlier.
  • the reaction of a compound of formula (IV) with a compound of formula (V) to produce a compound of formula (III) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
  • the inert atmosphere may be maintained by using inert gases such as N 2 , Ar or He.
  • the reaction may be effected in the presence of a base such as K 2 CO 3 , Na 2 CO 3 , NaH and the like. Mixture of bases may be used.
  • the reaction temperature may range from 20 °C to 150 °C, preferably at a temperature in the range of 30 °C to 100 °C.
  • the duration of the reaction may range from 1 to 24 hours, preferably from 2 to 6 hours.
  • the novel intermediate of general formula (III), where G is a CHO group can also be prepared by the reaction of compound of general formula (VI) where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, W, and n are as defined earlier and L 2 may be a halogen atom such as Cl, Br, I or a leaving group such as methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate with a compound of general formula (VII) HO ⁇ Ar ⁇ G where G is a CHO group and Ar is as defined earlier.
  • the reaction of a compound of formula (VI) with a compound of formula (VII) to produce a compound of the formula (III) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
  • the reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N 2 , Ar, or He.
  • the reaction may be effected in the presence of a base such as K 2 CO 3 , Na 2 CO 3 or NaH or mixtures thereof.
  • the reaction temperature may range from 20 °C - 120 °C, preferably at a temperature in the range of 30 °C - 100 °C.
  • the duration of the reaction may range from 1-12 hours, preferably from 2 to 6 hours.
  • a compound of general formula (III) can also be prepared by the reaction of compound of general formula (IV) defined earlier with a compound of general formula (VII) defined earlier.
  • reaction of compound of general formula (IV) with a compound of general formula (VII) may be carried out using suitable coupling agents such as dicyclohexyl urea, triarylphosphine/dialkylazadicarboxylate such as PPh 3 / DEAD and the like.
  • suitable coupling agents such as dicyclohexyl urea, triarylphosphine/dialkylazadicarboxylate such as PPh 3 / DEAD and the like.
  • the reaction may be carried out in the presence of solvents such as THF, DME, CH 2 Cl 2 , CHCl 3 , toluene, acetonitrile, carbontetrachloride and the like.
  • solvents such as THF, DME, CH 2 Cl 2 , CHCl 3 , toluene, acetonitrile, carbontetrachloride and the like.
  • the inert atmosphere may be maintained by using inert gases such as N 2 , Ar, and
  • the reaction may be effected in the presence of DMAP, HOBT and they may be used in the range of 0.05 to 2 equivalents, preferably 0.25 to 1 equivalents.
  • the reaction temperature may be in the range of 0 °C to 100°C, preferably at a temperature in the range of 20 °C to 80 °C.
  • the duration of the reaction may range from 0.5 to 24 hours, preferably from 6 to 12 hours.
  • the present invention provides a process for the preparation of novel azolidinedione derivatives of general formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, W, n, Ar and B are as defined earlier and R 7 together with R 8 represent a bond which comprises:
  • reaction of compound of the general formula (III) where G is a CHO group with 2,4-thiazolidinedione or 2,4-oxazolidinedione, to yield compound of general formula (VIII), may be carried out neat in the presence of sodium acetate or in the presence of a solvent such as benzene. toluene, methoxyethanol or mixtures thereof.
  • the reaction temperature may range from 80 °C to 140°C depending upon the solvents employed and in the range from 80 °C to 180°C when the reaction is carried out neat in the presence of sodium acetate.
  • Suitable catalyst such as piperidinium acetate or benzoate, sodium acetate or mixtures of catalysts may also be employed.
  • Sodium acetate can be used in the presence of solvent, but it is preferred that sodium acetate is used neat.
  • the water produced in the reaction may be removed, for example, by using Dean Stark water separator or by using water absorbing agents like molecular seives.
  • Oxazolidine-2-oxo-4-thione may be used instead of 2,4-oxazolidinedione, wherein the thio group may be converted to oxo group by oxidation using agents such as hydrogen peroxide or peroxyacids like mCPBA.
  • the compound of the general formula (VIII) obtained above is converted into its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates by conventional methods.
  • the compound of the general formula (VIII) obtained in the manner described above is reduced by known methods to obtain the compound of general formula (IX).
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, W, n, Ar and B are as defined earlier.
  • the compound of general formula (IX) represents a compound of general formula (I), wherein R 7 and R 8 represent hydrogen atoms and other symbols are as defined earlier.
  • the reduction of compound of the formula (VIII) to yield a compound of the general formula (IX) may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd/C. Rh/C, Pt/C, Raney nickel, and the like. Mixtures of catalysts may be used.
  • the reaction may also be conducted in the presence of solvents such as dioxane. acetic acid, ethyl acetate and the like or mixtures thereof. A pressure between atmospheric pressure and 80 psi may be employed.
  • the catalyst may be 5 - 10 % Pd/C and the amount of catalyst used may range from 50 - 300 % w/w.
  • the reaction may also be carried out by employing metal solvent reduction such as magnesium in methanol or sodium amalgam in methanol.
  • the reaction may also be carried out with alkali metal borohydrides such as LiBH 4 , NaBH 4 , KBH 4 and the like in the presence of cobalt salt such as CoCl 2 and ligands, preferably bidentated ligands such as 2, 2-bipyridyl, 1, 10-phenanthroline. bisoximes and the like.
  • alkali metal borohydrides such as LiBH 4 , NaBH 4 , KBH 4 and the like
  • cobalt salt such as CoCl 2 and ligands, preferably bidentated ligands such as 2, 2-bipyridyl, 1, 10-phenanthroline. bisoximes and the like.
  • the compound of the general formula (IX) obtained above is converted into its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates by conventional methods.
  • the compound of the general formula (I) can also be prepared by reacting a compound of the general formula (VI) defined above with a compound of general formula (X) where R 7 , R 8 , B and Ar are as defined earlier and R 10 is hydrogen or a nitrogen protecting group which is removed after the reaction.
  • the reaction of compound of formula (VI) with compound of formula (X) to produce a compound of the formula (I) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
  • the reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N 2 , Ar or He.
  • the reaction may be effected in the presence of a base such as K 2 CO 3 , Na 2 CO 3 or NaH or mixtures thereof.
  • the reaction temperature may range from 20°C - 150°C, preferably at a temperature in the range of 30°C- 80 °C.
  • the duration of the reaction may range from 1-12 hours, preferably from 2 to 6 hours.
  • compound of the general formula (I) can also be prepared by reacting a compound of general formula (IV) defined earlier with a compound of general formula (X) defined above.
  • reaction of compound of general formula (IV) with a compound of general formula (X) may be carried out using suitable coupling agents such as dicyclohexyl urea, triarylphosphine/dialkylazadicarboxylate such as PPh 3 / DEAD and the like.
  • the reaction may be carried out in the presence of solvents such as THE. DME, CH 2 Cl 2 , CHCl 3 , toluene, acetonitrile, carbontetrachloride and the like.
  • the inert atmosphere may be maintained by using inert gases such as N 2 , Ar, He,
  • the reaction may be effected in the presence of DMAP.
  • the reaction temperature may be in the range of 0°C to 100°C, preferably at a temperature in the range of 20°C to 80°C.
  • the duration of the reaction may range from 0.5 to 24 hours, preferably from 6 to 12 hours.
  • B represents S can be prepared by the reaction of compound of general formula (XI) where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, W, n, and Ar are as defined earlier, J is a halogen atom like chlorine, bromine or iodine and R is a lower alkyl group with thiourea followed by treatment with an acid.
  • the reaction of compound of general formula (XI) with thiourea is normally carried out in the presence of alcoholic solvent such as methanol. ethanol. propanol. isobutanol, 2-methoxybutanol and the like or DMSO or sulfolane.
  • alcoholic solvent such as methanol. ethanol. propanol. isobutanol, 2-methoxybutanol and the like or DMSO or sulfolane.
  • the reaction may be conducted at a temperature in the range between 20 °C and the reflux temperature of the solvent used.
  • Bases such as NaOAc. KOAc, NaOMe. NaOEt and the like may be used.
  • the reaction is normally followed by treatment with a mineral acid such as hydrochloric acid at 20°C - 100 °C.
  • the compound of general formula (XI) where all the symbols are as defined earlier can be prepared by the diazotization of the amino compound of the general formula (XII) where all symbols are as defined earlier, using alkali metal nitrites followed by treatment with acrylic acid esters in the presence of hydrohalo acids and catalytic amount of copper oxide or copper halide.
  • the compound of general formula (XII) can in turn be prepared by the conventional reduction of the novel intermediate (III) where G is NO 2 group and other symbols are as defined earlier.
  • the compound of general formula (I) can also be prepared by reacting the compound of general formula (XIII) where R 1 , R 2 , R 3 , R 4 , R 6 , X, and W are as defined earlier, with a compound of general formula (XIV) where Ar, R 5 , R 7 , R 8 , B and n are as defined earlier, and R 11 may be a linear or branched (C 1 -C 5 ) alkyl group such as methyl, ethyl, propyl, isopropyl, t-butyl and the like.
  • reaction of compound of general formula (XIV) with compound of general formula (XIII) to produce a compound of general formula (I) may be carried out in neat or in the presence of solvents such as THF, CHCl 3 , benzene, toluene, hexane, dioxane and the like or mixture thereof.
  • solvents such as THF, CHCl 3 , benzene, toluene, hexane, dioxane and the like or mixture thereof.
  • the reaction may be carried out at a temperature in the range of 0°C to 250 °C preferably at a temperature in the range of 10°C to 150°C.
  • the reaction may be carried out in the presence of an acid or a base. The selection of acid or base is not critical.
  • the examples of such acids include H 2 SO 4 , HCl, pTsOH, PPE (polyphosphoric ethyl ester) and the like.
  • bases include pyrrolidine, piperidine and the like.
  • the reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N 2 , Ar or He.
  • the duration of the reaction may range from 0.25 to 24 h preferably, from 1 to 12 h.
  • a process for the preparation of novel intermediate of general formula (XIV) as defined above, where all the symbols are as defined earlier comprises. reacting a compound of the general formula (XV) where all symbols are as defined earlier with a compound of general formula (X) where R 7 , R 8 , B and Ar are as defined earlier and R 10 is hydrogen or a nitrogen protecting group which is removed after the reaction.
  • the reaction of compound of formula (XV) with compound of formula (X) to produce a compound of the formula (XIV) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
  • the reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N 2 , Ar or He.
  • the reaction may be effected in the presence of a base such as K 2 CO 3 , Na 2 CO 3 or NaH or mixtures thereof.
  • the reaction temperature may range from 20°C - 120 °C, preferably at a temperature in the range of 30°C - 80 °C.
  • the duration of the reaction may range from 1 - 12 hours, preferably from 2 to 6 hours.
  • the compound of general formula (XIV) where R 7 and R 8 represents hydrogen atom and all other symbols are as defined earlier can be prepared from the compound of general formula (XVI) where all the symbols are as defined above, by reducing under known methods.
  • the reduction of compound of the formula (XVI) to yield a compound of the general formula (XIV) may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd/C, Rh/C, Pt/C, and the like. Mixtures of catalysts may be used.
  • the reaction may also be conducted in the presence of solvents such as dioxane, acetic acid, ethyl acetate and the like. A pressure between atmospheric pressure and 80 psi may be employed.
  • the catalyst may be 5 - 10 % Pd/C and the amount of catalyst used may range from 50 - 200 % w/w.
  • the reaction may also be carried out by employing metal solvent reduction such as magnesium in methanol or sodium amalgam in methanol.
  • the reaction may also be carried out with Raney Nickel in the presence of hydrogen gas or alkali metal borohydrides such as LiBH 4 , NaBH 4 , KBH 4 and the like in the presence of cobalt salt such as CoCl 2 and ligands, preferably bidentated ligands such as 2, 2'-bipyridyl, 1, 10-phenanthroline, bisoximes and the like.
  • alkali metal borohydrides such as LiBH 4 , NaBH 4 , KBH 4 and the like
  • cobalt salt such as CoCl 2 and ligands, preferably bidentated ligands such as 2, 2'-bipyridyl, 1, 10-phenanthroline, bisoximes and the like.
  • the present invention also provides a process for the preparation of novel intermediate of general formula (XVI) where all the symbols are as defined earlier, which comprises reacting the intermediate (XVII) where G represents CHO group, and all the symbols are as defined earlier, with 2,4-thiazolidinedione or 2,4-oxazolidinedione and removing the water formed during the reaction by conventional methods.
  • reaction between the compound of the general formula (XVII) where G is a CHO group with 2,4-thiazolidinedione or 2,4-oxazolidinedione, to yield compound of general formula (XVI) wherein B represents a sulfur or an oxygen atom respectively may be carried out neat in the presence of sodium acetate or in the presence of a solvent such as benzene, toluene. methoxyethanol or mixtures thereof.
  • the reaction temperature may range from 80 °C to 140 °C depending upon the solvents employed and in the range from 80 °C to 180 °C when the reaction is carried out neat in the presence of sodium acetate.
  • Suitable catalyst such as piperidinium acetate or benzoate, sodium acetate or mixtures of catalysts may also be employed.
  • Sodium acetate can be used in the presence of solvent, but it is preferred that sodium acetate is used neat.
  • the water produced in the reaction may be removed, for example, by using Dean Stark water separator or by using water absorbing agents like molecular seives.
  • Oxazolidine-2-oxo-4-thione may be used instead of 2,4-oxazolidinedione, wherein the thio group may be converted to oxo group by oxidation using agents such as hydrogen peroxide or peroxyacids like mCPBA.
  • the compound of formula (XVII) is in turn prepared by reacting a compound of formula (XV) where all symbols are as defined earlier and L 1 is a leaving group, with a compound of formula (VII) HO ⁇ Ar ⁇ G where G is a CHO group and Ar is as defined earlier.
  • the reaction of a compound of formula (XV) with a compound of formula (VII) to produce a compound of the formula (XVII) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
  • the reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N 2 , Ar, or He.
  • the reaction may be effected in the presence of a base such as K 2 CO 3 , Na 2 CO 3 or NaH or mixtures thereof.
  • the reaction temperature may range from 20°C - 120°C, preferably at a temperature in the range of 30°C - 100 °C.
  • the duration of the reaction may range from 1 - 12 hours, preferably from 2 to 6 hours.
  • the compound of formula (I) where R 7 and R 8 together represent a bond and all other symbols are as defined earlier may be prepared by reacting a compound of general formula (XVI) with a compound of general formula (XIII) using similar conditions as that followed for the reaction of compound of formula (XIII) with a compound of formula (XIV) as described earlier.
  • W represents NH and all other symbols are as defined earlier can also be prepared by reducing the compound of general formula (XVIII) (disclosed in copending US application Nos. 08/777,627 and 08/884,816).
  • R 7 and R 8 represents hydrogen atom or together form a bond and all other symbols are as defined earlier.
  • the reduction of compound of the formula (XVIII) to yield a compound of the general formula (I) may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd/C, Rh/C, Pt/C and the like. Mixture of catalysts may be used.
  • the reaction may also be carried out in the presence of solvents such as dioxane, acetic acid, ethyl acetate and the like. A pressure between atmospheric pressure and 80 psi may be employed.
  • the catalyst may be 5-10 % Pd/C and the amount of catalyst used may range from 30-50 w/w.
  • the duration of the reaction may range from 12 to 24 h and the temperature of the reaction may range from 25 °C to 80 °C.
  • the compound of general formula (VI) defined earlier may be prepared from compound of general formula (IV) defined earlier using conventional organic transformations that one skilled in the art would use.
  • the compound of general formula (VI) and of general formula (IV) defined earlier may be prepared by the reaction of compound of general formula (XIII) defined earlier with a compound of formula (XIX) where R 11 , R 5 and n are as defined earlier and Z represents hydroxy or a leaving group L 1 such as chloride, bromide, p-toluenesulfonate, methanesulfonate. trifluoromethanesulfonate and the like.
  • reaction of compound of (XIII) with a compound of formula (XIX) to yield a compound of formula (VI) or (IV) may be carried out using similar conditions described for the reaction of formula (XIII) with the compound of general formula (XIV).
  • the pharmaceutically acceptable salts are prepared by reacting the compound of formula (I) with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guanidine and their derivatives etc. may also be used. Alternatively, acid addition salts are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid. nitric acid.
  • acids such as hydrochloric acid, hydrobromic acid. nitric acid.
  • stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomeric form or by resolving the mixture of stereoisomers by conventional methods.
  • Some of the preferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid and the like or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like.
  • polymorphs of compound of general formula (I) forming part of this invention may be prepared by crystallization of compound of formula (I) under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization: crystallizations at different temperatures: various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe nmr spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
  • the present invention also provides a pharmaceutical composition, containing the compounds of the general formula (I), as defined above, their tautomeric forms. their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates or mixtures thereof in combination with the usual pharmaceutically employed carriers, diluents and the like, useful for the treatment and / or prophylaxis of hyperlipidemia, hypercholesterolemia, hyperglycemia, osteoporosis, obesity, glucose intolerance, insulin resistance and also diseases or conditions in which insulin resistance is the underlying pathophysiological mechanism such as type II diabetes, impaired glucose tolerance, dyslipidaemia, hypertension, coronary heart disease and other cardiovascular disorders including atherosclerosis; insulin resistance associated with obesity and psoriasis, for treating diabetic complications and other diseases such as polycystic ovarian syndrome (PCOS), certain renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive n
  • the pharmaceutical composition may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions, suspensions and the like, may contain flavourants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions.
  • Such compositions typically contain from 1 to 20 %, preferably 1 to 10 % by weight of active compound, the remainder of the composition being pharmaceutically acceptable carriers, diluents, excipients, or solvents.
  • a typical tablet production method is exemplified below :
  • the ingredients 1 to 3 are uniformly blended with water and granulated after drying under reduced pressure.
  • the ingredient 4 and 5 are mixed well with the granules and compressed by tabletting machine to prepare 1000 tablets each containing 10 mg of active ingredient.
  • ingredients 1 to 4 are uniformly moistened with an aqueous solution of ingredient 5 and granulated after drying under reduced pressure.
  • Ingredient 6 is added and granules are compressed by a tabletting machine to prepare 1000 tablets containing 10 mg of active ingredient 1.
  • the compound of the formula (I) as defined above are clinically administered to mammals, including man, via either oral or parenteral routes. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or absorption following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally.
  • the dosage is in the range of about 0.10 mg to about 200 mg / kg body weight of the subject per day or preferably about 0.10 mg to about 30 mg / kg body weight per day administered singly or as a divided dose.
  • the optimum dosage for the individual subject being treated will be determined by the person responsible for treatment, generally smaller doses being administered initially and thereafter increments made to determine the most suitable dosage.
  • Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions.
  • the active compound will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above.
  • the compounds can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like.
  • the pharmaceutical compositions may, if desired, contain additional components such as flavourants. sweeteners, excipients and the like.
  • the compounds can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil.
  • aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or salts with base of the compounds.
  • the injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.
  • Step A Preparation of 4-[2-oxo-propoxy]nitrobenzene -
  • 4-nitrophenol (25.0 g, 0.18 mol) and stirred for 30 min at 25 °C.
  • Chloroacetone (21.5 mL, 0.27 mol) was added to the reaction mixture and stirred for 24 h at 25- 30 °C.
  • the reaction mixture was filtered through a buchner funnel. The filtrate was poured into water (500 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 and concentrated.
  • Step B
  • ethyl acrylate (5.5 mL, 50.4 mmol) was added and allowed to warm to 30 °C. Catalytic amount of cuprous oxide (200 mg) was added in one portion and the reaction mixture was stirred further for 1h at 30 °C. Acetone was removed under reduced pressure. The resultant residue was extracted with ethyl acetate (3 x 25 mL). The combined organic layers were washed with ethyl acetate (3 x 25 mL), dilute NH 3 solution, water, followed by brine, dried over anhydrous Na 2 SO 4 . The solvent was evaporated under reduced pressure and the residue was purified by flash chromatography using EtOAc : pet.
  • the reaction mixture was cooled to room temperature, quenched with water (200 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 and concentrated.
  • the crude compound was purified by column chromatography using EtOAc : pet. ether (1 : 2) as eluent to yield the title compound (12.65 g, 58 %) as a brown coloured liquid.
  • Step B
  • the title compound (0.96 g, 95 %) was prepared from 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl methylene]thiazolidin-2,4-dione (1.0 g) (preparation described in copending US application numbers 08/777,627 and 08/884.816), by a similar procedure to that described in example 2.
  • the title compound (480 mg, 96 %) was prepared from 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl methyl]thiazolidin-2,4-dione (500 mg) (preparation described in copending US application numbers 08/777,627 and 08/884,816), by a similar procedure to that described in example 2.
  • the compounds of the present invention showed blood sugar and triglycerides lowering activities through improved insulin resistance. This was demonstrated by the following in vivo experiments.
  • mice of 8 to 14 weeks age having body weight range of 35 to 60 grams, procured from the Jackson Laboraotory, USA, were used in the experiment.
  • the mice were provided with standard feed (National Institute of Nutrition, Hyderabad, India) and acidified water, ad libitum.
  • the animals having more than 300 mg / dl blood sugar were used for testing.
  • the number of animals in each group was 4.
  • the random blood sugar and triglyceride levels were measured by collecting blood (100 ⁇ l) through orbital sinus, using heparinised capillary in tubes containing EDTA which was centrifuged to obtain plasma.
  • the plasma glucose and triglycerides levels were measured spectrometrically, by glucose oxidase and glycerol-3-PO 4 oxidase/peroxidase enzyme (Dr. Reddy's Lab. Diagnostic Division Kits, India) methods respectively.
  • the blood samples were collected one hour after administration of test compounds / vehicle for assessing the biological activity.
  • Test compounds were suspended on 0.25 % carboxymethyl cellulose and administered to test group at a dose of 1 mg to 100 mg / kg through oral gavage daily for 6 days.
  • the control group received vehicle (dose 10 ml / kg).
  • Troglitazone 100 mg / kg, daily dose was used as a standard drug which showed 28 % reduction in random blood sugar level on 6th day.
  • the compounds of the present invention also showed cholesterol lowering activity in the experimental animals used.

Abstract

The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their analogues, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinediones of general formula (I), their analogues, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

Description

  • The present invention relates to novel antidiabetic compounds, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinediones of the general formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
    Figure 00010001
  • The present invention also relates to a process for the preparation of the above said novel azolidinedione compounds, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, and pharmaceutically acceptable solvates; and pharmaceutical compositions containing them.
  • This invention also relates to novel intermediates, processes for preparing the intermediates and processes for using the intermediates.
  • The azolidinediones of the general formula (I) defined above of the present invention are useful for the treatment and / or prophylaxis of hyperlipidemia, hypercholesterolemia, hyperglycemia, osteoporosis, obesity, glucose intolerance, insulin resistance and also diseases or conditions in which insulin resistance is the underlying pathophysiological mechanism. Examples of these diseases and conditions are type II diabetes, impaired glucose tolerance, dyslipidaemia, hypertension, coronary heart disease and other cardiovascular disorders including atherosclerosis. The azolidinediones of formula (I) are useful for the treatment of insulin resistance associated with obesity and psoriasis. The azolidinediones of the formula (I) can also be used to treat diabetic complications and can be used for treatment and / or prophylaxis of other diseases and conditions such as polycystic ovarian syndrome (PCOS), certain renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal diseases and microalbuminuria as well as certain eating disorders, as aldose reductase inhibitors and for improving cognitive functions in dementia.
  • Background of the Invention
  • Insulin resistance is the diminished ability of insulin to exert its biological action across a broad range of concentrations. In insulin resistance, the body secretes abnormally high amounts of insulin to compensate for this defect; failing which, the plasma glucose concentration inevitably rises and develops into diabetes. Among the developed countries, diabetes mellitus is a common problem and is associated with a variety of abnormalities including obesity, hypertension, hyperlipidemia (J. Clin. Invest., (1985) 75 : 809 - 817; N. Engl. J. Med. (1987) 317 : 350 - 357 ; J. Clin. Endocrinol. Metab., (1988) 66 : 580 - 583; J. Clin. Invest., (1975) 68 : 957 - 969) and other renal complications (See Patent Application No. WO 95/21608). It is now increasingly being recognized that insulin resistance and relative hyperinsulinemia have a contributory role in obesity, hypertension, atherosclerosis and type 2 diabetes mellitus. The association of insulin resistance with obesity, hypertension and angina has been described as a syndrome having insulin resistance as the central pathogenic link-Syndrome-X. In addition, polycystic ovarian syndrome (Patent Application No. WO 95/07697), psoriasis (Patent Application No. WO 95/35108), dementia (Behavioral Brain Research (1996) 75 : 1 - 1 1 ) etc. may also have insulin resistance as a central pathogenic feature. Recently, it has also been reported that insulin sensitizers improve the bone mineral density and thus may be useful for the treatment of osteoporosis (EP-783888).
  • A number of molecular defects have been associated with insulin resistance. These include reduced expression of insulin receptors on the plasma membrane of insulin responsive cells and alterations in the signal transduction pathways that become activated after insulin binds to its receptor including glucose transport and glycogen synthesis.
  • Since defective insulin action is thought to be more important than failure of insulin secretion in the development of non-insulin dependent diabetes mellitus and other related complications, this raises doubts about the intrinsic suitability of antidiabetic treatment that is based entirely upon stimulation of insulin release. Recently, Takeda has developed a new class of compounds which are the derivatives of 5-(4-alkoxybenzyl)-2,4-thiazolidinediones of the formula (II) (Ref. Chem. Pharm. Bull. 1982, 30, 3580-3600). In the formula (II), V represents substituted or unsubstituted divalent aromatic group B represents a sulfur atom or an oxygen atom and U represents various groups which have been reported in various patent documents.
    Figure 00030001
    By way of examples, U may represent the following groups:
  • (i) a group of the formula (IIa) where R1 is hydrogen or hydrocarbon residue or heterocyclic residue which may each be substituted, R2 is hydrogen or a lower alkyl which may be substituted by hydroxy group, X is an oxygen or sulphur atom, Z is a hydroxylated methylene or a carbonyl, m is 0 or 1, n is an integer of 1-3. These compounds have been disclosed in the European Patent Application No. 0 177 353
    Figure 00030002
    An example of these compounds is shown in formula (IIb)
    Figure 00030003
  • (ii) a group of the formula (IIc) wherein R1 and R2 are the same or different and each represents hydrogen or C1-C5 alkyl, R3 represents hydrogen, acyl group, a (C1-C6) alkoxycarbonyl group or aralkyloxycarbonyl group, R4 - R5 are same or different and each represent hydrogen, C1 -C5 alkyl or C1 -C5 alkoxy or R4, R5 together represent C1-C4 alkenedioxy group, n is 1, 2, or 3, W represents CH2, CO, CHOR6 group in which R6 represents any one of the items or groups defined for R3 and may be the same or different from R3. These compounds are disclosed in the European Patent Application No. 0 139 421.
    Figure 00040001
    An example of these compounds is shown in (IId)
    Figure 00040002
  • iii) A group of formula (IIe) where A1 represents substituted or unsubstituted aromatic heterocyclic group, R1 represents a hydrogen atom, alkyl group, acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group, n represents an integer in the range from 2 to 6. These compounds are disclosed in European Patent No. 0 306 228.
    Figure 00040003
    An example of this compound is shown in formula (IIf)
    Figure 00040004
  • iv) A group of formula (IIg) where Y represents N or CR5, R1, R2, R3, R4and R5 represents hydrogen, halogen, alkyl and the like and R6 represents hydrogen. alkyl, aryl and the like, n represents an integer of 0 to 3. These compounds are disclosed in European Patent Application No. 0 604 983.
    Figure 00050001
    An example of this compound is shown in formula (IIh)
    Figure 00050002
  • v) a group of formula (IIi), where R is (C1-C6) alkyl groups, cycloalkyl group, furyl, thienyl, substituted or unsubstituted phenyl group. X is hydrogen, methyl, methoxy, chloro or fluoro.
    These compounds have been disclosed in the US patent no. 5 037 842.
    Figure 00050003
    An example of these compounds is shown in formula (IIj).
    Figure 00050004
  • (vi) a group of formula (IIk) wherein A1 represents a substituted or unsubstituted aromatic heterocyclyl group; R1 represents a hydrogen atom. an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstitutcd or a substituted or unsubstituted aryl group, n represents an integer in the range of from 2 to 6.
  • These compounds have been disclosed in the Patent Application No. WO 92/02520.
    Figure 00060001
  • An example of these compounds is shown in formula (II I).
    Figure 00060002
  • Some of the above referenced hitherto known antidiabetic compounds seem to possess bone marrow depression, liver and cardiac toxicities and modest potency and consequently, their regular use for the treatment and control of diabetes is becoming limited and restricted.
  • Compounds of the formula
  • Figure 00060003
    wherein R1 represents an alkyl group, alkoxy group, halogen atom, halogenoalkyl group, amino group, hydroxy group, benzyloxy group which may have a substituent, cyano group, carbamoyl group, acyl group, nitro group, carboxy group, or sulfonamide group; R2 and R3 may be the same or different and each individually represents a hydrogen atom or an alkyl group, or R2 and R3 indicate in combination an alkylene group having 2-7 carbon atoms; R4 and R5 may be the same or different and each individually represents a hydrogen atom or an alkyl group; X denotes O, S, or N-R6 (wherein R6 represents a hydrogen atom, an alkyl group, or an aryl group or pyridyl group which may have a substituent); m is an integer from 0 to 4; and n is an integer from 1 to 3 have been disclosed in EP 0 787 727 Al.
  • Summary of the Invention
  • With an objective of developing new compounds for the treatment of type II diabetes [non-insulin-dependent-diabetes mellitus (NIDDM)] which could be more potent at relatively lower doses and having better efficacy with lower toxicity, we focused our research efforts in a direction of incorporating safety and to have better efficacy, which has resulted in the development of novel azolidinedione compounds having the general formula (I) as defined above.
  • The main objective of the present invention is therefore, to provide novel azolidinediones, their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them and mixtures thereof.
  • Another objective of the present invention is to provide novel azolidinedione compounds, their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them and mixtures thereof having enhanced activities, no toxic effect or reduced toxic effect.
  • Yet another objective of the present invention is to provide a process for the preparation of novel azolidinediones of the formula (I) as defined above, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates.
  • Still another objective of the present invention is to provide pharmaceutical compositions containing compounds of the general formula (I), their tautomers, their stereoisomers, their polymorphs, their salts, solvates or mixtures thereof in combination with suitable carriers, solvents, diluents, excipients and other media normally employed in preparing such compositions.
  • Yet another objective of the present invention is to provide novel intermediates of the formula (III)
    Figure 00090001
       where G represents -CHO, -NH2 or -CH2CH(J)-COOR, where J represents halogen atom such as chlorine, bromine or iodine and R represents H or lower alkyl group such as (C1 - C6) alkyl group, preferably a (C1- C3) alkyl group such as methyl, ethyl, or propyl; and R1, R2, R3, R4, R5, R6, X, W, n and Ar are defined as in formula (I).
  • Still another objective of the present invention is to provide a process for the preparation of the novel intermediates of the formula (III)
    Figure 00100001
       where G represents -CHO, -NH2 or -CH2CH(J)-COOR, where J represents halogen atom such as chlorine, bromine or iodine and R represents H or lower alkyl group such as (C1 - C6) alkyl group, preferably a (C1 - C3) alkyl group such as methyl, ethyl, or propyl; and R1, R2, R3, R4, R5, R6, X, W, n and Ar are defined as in formula (I).
  • Detailed Description of the Invention
  • Azolidinediones of the present invention have the general formula (I)
    Figure 00100002
    In the above formula (I), X represents O or S; the groups R1, R2, R3, R4 may be same or different and represent hydrogen, halogen, hydroxy, cyano, nitro; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkyloxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, aryloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylamino, arylamino, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, acyl, acylamino, aryloxycarbonylamino, aralkoxycarbonylamino, alkoxycarbonylamino, carboxylic acid or its optionally substituted amides, acyloxy, sulfonic acid or its optionally substituted amides; W represents O, S or a group NR9; R6 and R9 may be same or different and represent hydrogen; or optionally substituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, hydroxyalkyl, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acyl, hydroxyalkyl, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, alkylthio, or thioalkyl groups; R5 represents hydrogen, hydroxy, or halogen atom or optionally substituted alkyl, aryl, heteroaryl, acyl, alkoxy, aralkyl, or aralkoxy; n is an integer ranging from 1 - 4; Ar represent an optionally substituted divalent aromatic or heterocyclic group; R7 and R8 may be same or different and individually represents hydrogen atom, halogen, hydroxy, lower alkyl, optionally substituted aralkyl group or together form a bond ; and B represents an oxygen atom or a sulfur atom.
  • Suitable groups represented by R1, R2, R3, R4 may be selected from hydrogen, halogen atom such as fluorine, chlorine, bromine, or iodine; hydroxy, cyano, nitro; substituted or unsubstituted (C1-C12)alkyl group, especially, linear or branched (C1-C6)alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, t-butyl, n-pentyl, isopentyl, hexyl and the like: cycloalkyl group such as cyclopropyl. cyclobutyl, cyclopentyl, cyclohexyl and the like, cycloalkyl group may be substituted: cycloalkyloxy group such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like, cycloalkyloxy group may be substituted; aryl group such as phenyl or naphthyl, the aryl group may be substituted; aralkyl such as benzyl or phenethyl, the aralkyl group may be substituted: heteroaryl group such as pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, tetrazolyl, benzopyranyl, benzofuranyl and the like, the heteroaryl group may be substituted; heteroaralkyl wherein the heteroaryl moiety is as defined earlier and is attached to (C1 - C3) alkylene group such as furanmethyl, pyridinemethyl, oxazolemethyl, oxazolethyl, and the like, the heteroaralkyl group may be substituted; heterocyclyl groups such as aziridinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl and the like. the heterocyclyl group may be substituted; aryloxy such as phenoxy, naphthyloxy, the aryloxy group may be substituted; alkoxycarbonyl such as methoxycarbonyl or ethoxycarbonyl, the alkoxycarbonyl group may be substituted; aryloxycarbonyl group such as optionally substituted phenoxycarbonyl or naphthyloxycarbonyl; substituted or unsubstituted aralkoxycarbonyl wherein the aryl moiety is phenyl or naphthyl, such as benzyloxycarbonyl, phenethyloxycarbonyl. naphthylmethyloxycarbonyl and the like; linear or branched (C1 - C6) alkylamino: arylamino group such as HNC6H5; -NCH3C6H5, -NHC6H4-CH3, -NHC6H4-halo and the like, amino group: amino(C1-C6)alkyl: hydroxy(C1-C6)alkyl; (C1-C6)alkoxy; alkoxyalkyl such as methoxymethyl, ethoxymethyl, methoxyethyl and the like; thio(C1-C6)alkyl; (C1-C6)alkylthio; acyl group such as acetyl, propionyl or benzoyl, the acyl group may be substituted; acylamino groups such as NHCOCH3, NHCOC2H5, NHCOC3H7, NHCOC6H5, aralkoxycarbonylamino group such as NHCOOCH2C6H5 - NHCOOCH2CH2C6H5, -NCH3COOCH2C6H5,-NC2H5COOCH2C6H5,-NHCOOCH2C6H4CH3,-NHCOOCH2C6H4OCH3 and the like, alkoxycarbonyl amino group such as NHCOOC2H5, NHCOOCH3 and the like; aryloxycarbonylamino group such as NHCOOC6H5, -NCH3COOC6H5, -NC2H5COOC6H5, -NHCOOC6H4CH3, -NHCOOC6H4OCH3 and the like; carboxylic acid or its derivatives such as amides, like CONH2, CONHMe, CONMe2, CONHEt, CONEt2, CONHPh and the like, the carboxylic acid derivatives may be substituted; acyloxy group such as MeCOO, EtCOO, PhCOO and the like, which may optionally be substituted; sulfonic acid or its derivatives such as SO2NH2, SO2NHMe, SO2NMe2, SO2NHCF3 and the like, the sulfonic acid derivatives may be substituted.
  • The alkoxy, alkylamino, arylamino, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, acylamino, aryloxycarbonylamino, aralkoxycarbonylamino, and alkoxycarbonylamino groups may also be substituted.
  • When the groups represented by R1, R2, R3, R4 are substituted, the substituents may be selected from halogen, hydroxy, cyano, nitro, alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, acyloxy, hydroxyalkyl, amino, acylamino, arylamino, aminoalkyl, aryloxy, alkoxycarbonyl, alkylamino such as NHCH3, N(CH3)2, NCH3(C2H5), NHC2H5 and the like; alkoxyalkyl such as methoxymethyl, ethoxymethyl, methoxyethyl and the like; alkylthio, thioalkyl groups, carboxylic acid or its optionally substituted amides, or sulfonic acid or its optionally substituted amides.
  • These groups are as defined above for R1 - R4.
  • It is preferred that R1 - R4 represent hydrogen; halogen atom such as fluorine, chlorine, bromine; alkyl group such as methyl, ethyl, isopropyl, n-propyl, n-butyl; and the like which may be halogenated; optionally halogenated groups selected from cycloalkyl group such as cyclopropyl; aryl group such as phenyl; aralkyl group such as benzyl; (C1-C3)alkoxy, aryloxy group such as benzyloxy, hydroxy group, acyl or acyloxy groups. Acyl and acyloxy groups are as defined above.
  • Suitable R6 and R9 are selected from hydrogen, substituted or unsubstituted (C1-C12)alkyl group, especially, linear or branched (C1-C6)alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, t-butyl, n-pentyl, isopentyl, hexyl and the like; substituted or unsubstituted cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like; aryl group such as phenyl or naphthyl, the aryl group may be substituted; aralkyl group such as benzyl or phenethyl, the aralkyl group may be substituted; heteroaryl group such as pyridyl, thienyl, furyl and the like, the heteroaryl group may be substituted; substituted or unsubstituted heterocyclyl such as aziridinyl, pyrrolidinyl, morpholinyl, piperidinyl and the like; substituted or unsubstituted heteroaralkyl such as pyridylmethyl, furanmethyl, oxazolemethyl, oxazolethyl and the like; substituted or unsubstituted alkoxyalkyl such as methoxymethyl, ethoxymethyl, ethoxyethyl, methoxyethyl and the like: substituted or unsubstituted alkylthio such as SCH3, SC2H5, SC3H7 and the like; substituted or unsubstituted alkoxycarbonyl such as methoxycarbonyl or ethoxycarbonyl; aryloxycarbonyl group such as optionally substituted phenoxycarbonyl or naphthyloxycarbonyl; substituted or unsubstituted aralkoxycarbonyl group such as benzyloxycarbonyl, napthylmethoxycarbonyl; amino(C1-C6)alkyl; hydroxy(C1-C6)alkyl; thio(C1-C6)alkyl; and acyl group such as acetyl, propionyl or benzoyl. The acyl, aminoalkyl, hydroxyalkyl and thioalkyl groups may be substituted.
  • When the groups represented by R6, R9 are substituted, the preferred substituents are halogen such as fluorine, chlorine; hydroxy, acyl. acyloxy, and amino groups.
  • The acyl and acyloxy groups are as defined above.
  • Suitable R5 may be hydrogen, halogen, hydroxy or optionally substituted (C1-C6)alkyl group which may be linear or branched, aryl. heteroaryl, (C1-C6)alkoxy, aralkyl, arakoxy, or acyl groups.
  • R5 may be substituted by hydroxy. halogen. linear or branched (C1-C6) alkyl group, acyl or acyloxy group.
  • These groups are as defined above.
  • n is an integer ranging from 1 - 4. It is preferred that n be I or 2.
  • It is preferred that the group represented by Ar be substituted or unsubstituted groups selected from divalent phenylene, naphthylene, pyridyl, quinolinyl, benzofuryl, dihydrobenzofuryl, benzopyranyl, indolyl, indolinyl, azaindolyl, azaindolinyl, pyrazolyl, benzothiazolyl, benzoxazolyl and the like. The substituents on the group represented by Ar may be selected from linear or branched (C1-C6)alkyl, (C1-C3)alkoxy, halogen, acyl, amino, acylamino, thio or carboxylic or sulfonic acids and their derivatives.
  • It is more preferred that Ar represents substituted or unsubstituted divalent phenylene, naphthylene, benzofuryl, indolyl, indolinyl, quinolinyl, azaindolyl, azaindolinyl, benzothiazolyl or benzoxazolyl.
  • It is still more preferred that Ar represents divalent phenylene or naphthylene, which may be optionally substituted by methyl, halomethyl, methoxy or halomethoxy groups.
  • Suitable R7 includes hydrogen, hydroxy, lower alkyl group such as (C1-C6)alkyl such as methyl, ethyl or propyl; substituted or unsubstituted aralkyl group such as benzyl, phenethyl CH2C6H4-Halo, CH2C6H4-OCH3, CH2C6H4CH3, CH2CH2C6H4CH3 and the like; halogen atom such as fluorine, chlorine bromine or iodine: or R7 together with R8 represents a bond.
  • It is preferred that R7 represents hydrogen or a bond together with R8.
  • Suitable R8 represents hydrogen, hydroxy, lower alkyl group such as (C1-C6)alkyl such as methyl, ethyl or propyl; substituted or unsubstituted aralkyl group such as benzyl, phenethyl, CH2C6H4-Halo, CH2C6H4-OCH3, CH2C6H4CH3, CH2CH2C6H4CH3 and the like; halogen atom such as fluorine, chlorine, bromine or odine; or together with R7 forms a bond.
  • When R7 or R8 is lower alkyl, the lower alkyl may be substituted by groups such as halogen, methyl or oxo group.
  • Suitable B group includes a hetero atom selected from O or S.
  • Suitable ring structure comprising B include 2.4-dioxooxazolidinyl, 2.4-dioxothiazolidinyl groups.
  • It is more preferred that the ring structure comprising B is a 2,4-dioxothiazolidinyl group.
  • The groups represented by R1 - R9 and any substituents on these groups may be defined as disclosed anywhere in the specification.
  • Pharmaceutically acceptable salts forming part of this invention include salts of the azolidinedione moiety such as alkali metal salts like Li, Na. and K salts. alkaline earth metal salts like Ca and Mg salts, salts of organic bases such as lysine, arginine, guanidine, diethanolamine, choline and the like, ammonium or substituted ammonium salts, salts of carboxy group wherever appropriate, such as aluminum, alkali metal salts; alkaline earth metal salts, ammonium or substituted ammonium salts. Salts may include acid addition salts which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulfonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like. Pharmaceutically acceptable solvates may be hydrates or comprising other solvents of crystallization such as alcohols.
  • Particularly useful compounds according to the present invention include :
  • 5-[4-[[4-Oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl]thiazolidin-2,4-dione;
  • 5-[4-[[3-Methyl-4-oxo-3.4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl] thiazolidin-2,4-dione;
  • 5-[4-[[3-Ethyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl] thiazolidin-2.4-dione;
  • 5-[4-[2,3-Dimethyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl] thiazolidin-2,4-dione;
  • 5-[4-[[4-Oxo-3,4-dihydro-(2H)- 1,3-benzoxazine-2-yl]methoxy]phenyl methyl]thiazolidin-2,4-dione, sodium salt;
  • 5-[4-((3-Methyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl] thiazolidin-2,4-dione, sodium salt;
  • 5-[4-[[1.3-Dimethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methylene]thiazolidin-2,4-dione;
  • 5-[4-[[3-Methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methylene] thiazolidin-2,4,dione;
  • 5-[4-[[1.3-Dimethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione;
  • 5-[4-[[3-Methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2.4-dione;
  • 5-(4-[[3-Ethyl-1-methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2.4-dione;
  • 5-[4-[[1-Methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione;
  • 5-[4-[[1,3-Dimethyl-4-oxo- 1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione, sodium salt;
  • 5-[4-[[4-Oxo-1,2,3.4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl]thiazolidin-2,4-dione;
  • 5-[4-[[1,3-Diethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione;
  • 5-[ 4-[[ 1-Ethyl-3-methyl-4-oxo-1.2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2.4-dione; and
  • 5-[4-[[1-Ethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione.
  • The invention also includes an intermediate of formula (III)
    Figure 00180001
    wherein X represents O or S; the groups R1, R2, R3, R4 may be same or different and represent hydrogen, halogen, hydroxy, cyano, nitro; optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkyloxy, aryl, aralkyl, heteroaryl. heteroaralkyl, heterocyclyl, aryloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylamino, arylamino, amino. aminoalkyl, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, acyl, acylamino, aryloxycarbonylamino, aralkoxycarbonylamino, alkoxycarbonylamino, carboxylic acid or its derivatives, acyloxy, sulfonic acid or its derivatives; W represents O, S or a group NR9; R6 and R9 may be same or different and represent hydrogen or optionally substituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl. acyl, hydroxyalkyl. aminoalkyl, alkoxycarbonyl, aryloxycarbonyl. aralkoxycarbonyl, alkoxyalkyl alkylthio, or thioalkyl groups; R5 represents hydrogen, hydroxy or halogen or optionally substituted alkyl, aryl, heteroaryl, acyl, alkoxy, aralkyl, or aralkoxy; n is an integer ranging from 1 - 4; Ar represents an optionally substituted divalent aromatic or heterocyclic group; G represents CHO, -NH2 or -CH2CH(J)-COOR, where J represents a halogen atom and R represents H or lower alkyl group.
  • According to a feature of the present invention, there is provided a process for the preparation of novel intermediate of the general formula (III)
    Figure 00190001
    where R1, R2, R3, R4, R5, R6, X, W, n, and Ar are as defined earlier, G represents -CHO group which comprises, reacting a compound of the general formula (IV)
    Figure 00190002
       wherein, R1, R2, R3, R4, R5, R6, X, W, and n are as defined earlier, with a compound of general formula (V) L1―Ar―G    where L1 is a halogen atom such as fluorine or chlorine, G is a CHO group and Ar is as defined earlier.
  • The reaction of a compound of formula (IV) with a compound of formula (V) to produce a compound of formula (III) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof. The inert atmosphere may be maintained by using inert gases such as N2, Ar or He. The reaction may be effected in the presence of a base such as K2CO3, Na2CO3, NaH and the like. Mixture of bases may be used. The reaction temperature may range from 20 °C to 150 °C, preferably at a temperature in the range of 30 °C to 100 °C. The duration of the reaction may range from 1 to 24 hours, preferably from 2 to 6 hours.
  • In another embodiment of the present invention, the novel intermediate of general formula (III), where G is a CHO group, can also be prepared by the reaction of compound of general formula (VI)
    Figure 00210001
    where R1, R2, R3, R4, R5, R6, X, W, and n are as defined earlier and L2 may be a halogen atom such as Cl, Br, I or a leaving group such as methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate with a compound of general formula (VII) HO―Ar―G    where G is a CHO group and Ar is as defined earlier.
  • The reaction of a compound of formula (VI) with a compound of formula (VII) to produce a compound of the formula (III) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N2, Ar, or He. The reaction may be effected in the presence of a base such as K2CO3, Na2CO3 or NaH or mixtures thereof. The reaction temperature may range from 20 °C - 120 °C, preferably at a temperature in the range of 30 °C - 100 °C. The duration of the reaction may range from 1-12 hours, preferably from 2 to 6 hours.
  • Alternatively, a compound of general formula (III) can also be prepared by the reaction of compound of general formula (IV) defined earlier with a compound of general formula (VII) defined earlier.
  • The reaction of compound of general formula (IV) with a compound of general formula (VII) may be carried out using suitable coupling agents such as dicyclohexyl urea, triarylphosphine/dialkylazadicarboxylate such as PPh3 / DEAD and the like. The reaction may be carried out in the presence of solvents such as THF, DME, CH2Cl2, CHCl3, toluene, acetonitrile, carbontetrachloride and the like. The inert atmosphere may be maintained by using inert gases such as N2, Ar, and He. The reaction may be effected in the presence of DMAP, HOBT and they may be used in the range of 0.05 to 2 equivalents, preferably 0.25 to 1 equivalents. The reaction temperature may be in the range of 0 °C to 100°C, preferably at a temperature in the range of 20 °C to 80 °C. The duration of the reaction may range from 0.5 to 24 hours, preferably from 6 to 12 hours.
  • The present invention provides a process for the preparation of novel azolidinedione derivatives of general formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates wherein R1, R2, R3, R4, R5, R6, X, W, n, Ar and B are as defined earlier and R7 together with R8 represent a bond which comprises:
  • reacting the novel intermediate of the general formula (III) obtained above
  • where G represents CHO group with 2.4-thiazolidinedione or 2,4-oxazolidinedione and removing the water formed during the reaction by conventional methods to yield a compound of general formula (VIII)
    Figure 00220001
    where R1, R2, R3, R4, R5, R6, X, W, n, and Ar are as defined earlier and B represents sulfur or oxygen. The compound of general formula (VIII) represents a compound of general formula (I), wherein R7 and R8 together represent a bond and all other symbols are as defined earlier.
  • The reaction of compound of the general formula (III) where G is a CHO group with 2,4-thiazolidinedione or 2,4-oxazolidinedione, to yield compound of general formula (VIII), may be carried out neat in the presence of sodium acetate or in the presence of a solvent such as benzene. toluene, methoxyethanol or mixtures thereof. The reaction temperature may range from 80 °C to 140°C depending upon the solvents employed and in the range from 80 °C to 180°C when the reaction is carried out neat in the presence of sodium acetate. Suitable catalyst such as piperidinium acetate or benzoate, sodium acetate or mixtures of catalysts may also be employed. Sodium acetate can be used in the presence of solvent, but it is preferred that sodium acetate is used neat. The water produced in the reaction may be removed, for example, by using Dean Stark water separator or by using water absorbing agents like molecular seives. Oxazolidine-2-oxo-4-thione may be used instead of 2,4-oxazolidinedione, wherein the thio group may be converted to oxo group by oxidation using agents such as hydrogen peroxide or peroxyacids like mCPBA.
  • The compound of the general formula (VIII) obtained above is converted into its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates by conventional methods.
  • The compound of the general formula (VIII) obtained in the manner described above is reduced by known methods to obtain the compound of general formula (IX).
    Figure 00230001
    wherein R1, R2, R3, R4, R5, R6, X, W, n, Ar and B are as defined earlier. The compound of general formula (IX) represents a compound of general formula (I), wherein R7 and R8 represent hydrogen atoms and other symbols are as defined earlier.
  • The reduction of compound of the formula (VIII) to yield a compound of the general formula (IX) may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd/C. Rh/C, Pt/C, Raney nickel, and the like. Mixtures of catalysts may be used. The reaction may also be conducted in the presence of solvents such as dioxane. acetic acid, ethyl acetate and the like or mixtures thereof. A pressure between atmospheric pressure and 80 psi may be employed. The catalyst may be 5 - 10 % Pd/C and the amount of catalyst used may range from 50 - 300 % w/w. The reaction may also be carried out by employing metal solvent reduction such as magnesium in methanol or sodium amalgam in methanol. The reaction may also be carried out with alkali metal borohydrides such as LiBH4, NaBH4, KBH4 and the like in the presence of cobalt salt such as CoCl2 and ligands, preferably bidentated ligands such as 2, 2-bipyridyl, 1, 10-phenanthroline. bisoximes and the like.
  • The compound of the general formula (IX) obtained above is converted into its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates by conventional methods.
  • In yet another embodiment of the present invention, the compound of the general formula (I) can also be prepared by reacting a compound of the general formula (VI) defined above with a compound of general formula (X)
    Figure 00240001
    where R7, R8, B and Ar are as defined earlier and R10 is hydrogen or a nitrogen protecting group which is removed after the reaction.
  • The reaction of compound of formula (VI) with compound of formula (X) to produce a compound of the formula (I) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N2, Ar or He. The reaction may be effected in the presence of a base such as K2CO3, Na2CO3 or NaH or mixtures thereof. The reaction temperature may range from 20°C - 150°C, preferably at a temperature in the range of 30°C- 80 °C. The duration of the reaction may range from 1-12 hours, preferably from 2 to 6 hours.
  • Alternatively, compound of the general formula (I) can also be prepared by reacting a compound of general formula (IV) defined earlier with a compound of general formula (X) defined above.
  • The reaction of compound of general formula (IV) with a compound of general formula (X) may be carried out using suitable coupling agents such as dicyclohexyl urea, triarylphosphine/dialkylazadicarboxylate such as PPh3 / DEAD and the like. The reaction may be carried out in the presence of solvents such as THE. DME, CH2Cl2, CHCl3, toluene, acetonitrile, carbontetrachloride and the like. The inert atmosphere may be maintained by using inert gases such as N2, Ar, He, The reaction may be effected in the presence of DMAP. HOBT and they may be used in the range of 0.05 to 2 equivalents, preferably 0.25 to 1equivalents. The reaction temperature may be in the range of 0°C to 100°C, preferably at a temperature in the range of 20°C to 80°C. The duration of the reaction may range from 0.5 to 24 hours, preferably from 6 to 12 hours.
  • In another embodiment of the present invention, the compound of general formula (I), where R1, R2, R3, R4, R5, R6, X, W, n, and Ar are as defined earlier and R7 and R8 represent hydrogen atoms, B represents S can be prepared by the reaction of compound of general formula (XI)
    Figure 00250001
    where R1, R2, R3, R4, R5, R6, X, W, n, and Ar are as defined earlier, J is a halogen atom like chlorine, bromine or iodine and R is a lower alkyl group with thiourea followed by treatment with an acid.
  • The reaction of compound of general formula (XI) with thiourea is normally carried out in the presence of alcoholic solvent such as methanol. ethanol. propanol. isobutanol, 2-methoxybutanol and the like or DMSO or sulfolane. The reaction may be conducted at a temperature in the range between 20 °C and the reflux temperature of the solvent used. Bases such as NaOAc. KOAc, NaOMe. NaOEt and the like may be used. The reaction is normally followed by treatment with a mineral acid such as hydrochloric acid at 20°C - 100 °C.
  • The compound of general formula (XI) where all the symbols are as defined earlier can be prepared by the diazotization of the amino compound of the general formula (XII)
    Figure 00260001
    where all symbols are as defined earlier, using alkali metal nitrites followed by treatment with acrylic acid esters in the presence of hydrohalo acids and catalytic amount of copper oxide or copper halide.
  • The compound of general formula (XII) can in turn be prepared by the conventional reduction of the novel intermediate (III) where G is NO2 group and other symbols are as defined earlier.
  • In yet another embodiment of the present invention, the compound of general formula (I), can also be prepared by reacting the compound of general formula (XIII)
    Figure 00260002
    where R1, R2, R3, R4, R6, X, and W are as defined earlier, with a compound of general formula (XIV)
    Figure 00260003
    where Ar, R5, R7, R8, B and n are as defined earlier, and R11 may be a linear or branched (C1-C5) alkyl group such as methyl, ethyl, propyl, isopropyl, t-butyl and the like.
  • The reaction of compound of general formula (XIV) with compound of general formula (XIII) to produce a compound of general formula (I) may be carried out in neat or in the presence of solvents such as THF, CHCl3, benzene, toluene, hexane, dioxane and the like or mixture thereof. The reaction may be carried out at a temperature in the range of 0°C to 250 °C preferably at a temperature in the range of 10°C to 150°C. The reaction may be carried out in the presence of an acid or a base. The selection of acid or base is not critical. The examples of such acids include H2SO4, HCl, pTsOH, PPE (polyphosphoric ethyl ester) and the like. Examples of bases include pyrrolidine, piperidine and the like. The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N2, Ar or He. The duration of the reaction may range from 0.25 to 24 h preferably, from 1 to 12 h.
  • In another embodiment of the present invention, there is provided a process for the preparation of novel intermediate of general formula (XIV) as defined above, where all the symbols are as defined earlier which comprises. reacting a compound of the general formula (XV)
    Figure 00270001
    where all symbols are as defined earlier with a compound of general formula (X) where R7, R8, B and Ar are as defined earlier and R10 is hydrogen or a nitrogen protecting group which is removed after the reaction.
  • The reaction of compound of formula (XV) with compound of formula (X) to produce a compound of the formula (XIV) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N2, Ar or He. The reaction may be effected in the presence of a base such as K2CO3, Na2CO3 or NaH or mixtures thereof. The reaction temperature may range from 20°C - 120 °C, preferably at a temperature in the range of 30°C - 80 °C. The duration of the reaction may range from 1 - 12 hours, preferably from 2 to 6 hours.
  • In still another embodiment of the present invention, the compound of general formula (XIV) where R7 and R8 represents hydrogen atom and all other symbols are as defined earlier can be prepared from the compound of general formula (XVI)
    Figure 00280001
    where all the symbols are as defined above, by reducing under known methods.
  • The reduction of compound of the formula (XVI) to yield a compound of the general formula (XIV) may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd/C, Rh/C, Pt/C, and the like. Mixtures of catalysts may be used. The reaction may also be conducted in the presence of solvents such as dioxane, acetic acid, ethyl acetate and the like. A pressure between atmospheric pressure and 80 psi may be employed. The catalyst may be 5 - 10 % Pd/C and the amount of catalyst used may range from 50 - 200 % w/w. The reaction may also be carried out by employing metal solvent reduction such as magnesium in methanol or sodium amalgam in methanol.
  • The reaction may also be carried out with Raney Nickel in the presence of hydrogen gas or alkali metal borohydrides such as LiBH4, NaBH4, KBH4 and the like in the presence of cobalt salt such as CoCl2 and ligands, preferably bidentated ligands such as 2, 2'-bipyridyl, 1, 10-phenanthroline, bisoximes and the like.
  • The present invention also provides a process for the preparation of novel intermediate of general formula (XVI) where all the symbols are as defined earlier, which comprises reacting the intermediate (XVII)
    Figure 00280002
    where G represents CHO group, and all the symbols are as defined earlier, with 2,4-thiazolidinedione or 2,4-oxazolidinedione and removing the water formed during the reaction by conventional methods.
  • The reaction between the compound of the general formula (XVII) where G is a CHO group with 2,4-thiazolidinedione or 2,4-oxazolidinedione, to yield compound of general formula (XVI) wherein B represents a sulfur or an oxygen atom respectively, may be carried out neat in the presence of sodium acetate or in the presence of a solvent such as benzene, toluene. methoxyethanol or mixtures thereof. The reaction temperature may range from 80 °C to 140 °C depending upon the solvents employed and in the range from 80 °C to 180 °C when the reaction is carried out neat in the presence of sodium acetate. Suitable catalyst such as piperidinium acetate or benzoate, sodium acetate or mixtures of catalysts may also be employed. Sodium acetate can be used in the presence of solvent, but it is preferred that sodium acetate is used neat. The water produced in the reaction may be removed, for example, by using Dean Stark water separator or by using water absorbing agents like molecular seives. Oxazolidine-2-oxo-4-thione may be used instead of 2,4-oxazolidinedione, wherein the thio group may be converted to oxo group by oxidation using agents such as hydrogen peroxide or peroxyacids like mCPBA.
  • The compound of formula (XVII) is in turn prepared by reacting a compound of formula (XV)
    Figure 00290001
    where all symbols are as defined earlier and L1 is a leaving group, with a compound of formula (VII) HO―Ar―G where G is a CHO group and Ar is as defined earlier.
  • The reaction of a compound of formula (XV) with a compound of formula (VII) to produce a compound of the formula (XVII) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N2, Ar, or He. The reaction may be effected in the presence of a base such as K2CO3, Na2CO3 or NaH or mixtures thereof. The reaction temperature may range from 20°C - 120°C, preferably at a temperature in the range of 30°C - 100 °C. The duration of the reaction may range from 1 - 12 hours, preferably from 2 to 6 hours.
  • In another embodiment of the present invention the compound of formula (I) where R7 and R8 together represent a bond and all other symbols are as defined earlier may be prepared by reacting a compound of general formula (XVI) with a compound of general formula (XIII) using similar conditions as that followed for the reaction of compound of formula (XIII) with a compound of formula (XIV) as described earlier.
  • In yet another embodiment of the present invention, the compound of general formula (I) where R5 is hydrogen atom. W represents NH and all other symbols are as defined earlier can also be prepared by reducing the compound of general formula (XVIII) (disclosed in copending US application Nos. 08/777,627 and 08/884,816).
    Figure 00300001
    where R7 and R8 represents hydrogen atom or together form a bond and all other symbols are as defined earlier.
  • The reduction of compound of the formula (XVIII) to yield a compound of the general formula (I) may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd/C, Rh/C, Pt/C and the like. Mixture of catalysts may be used. The reaction may also be carried out in the presence of solvents such as dioxane, acetic acid, ethyl acetate and the like. A pressure between atmospheric pressure and 80 psi may be employed. The catalyst may be 5-10 % Pd/C and the amount of catalyst used may range from 30-50 w/w. The duration of the reaction may range from 12 to 24 h and the temperature of the reaction may range from 25 °C to 80 °C.
  • The compound of general formula (VI) defined earlier may be prepared from compound of general formula (IV) defined earlier using conventional organic transformations that one skilled in the art would use.
  • The compound of general formula (VI) and of general formula (IV) defined earlier may be prepared by the reaction of compound of general formula (XIII) defined earlier with a compound of formula (XIX)
    Figure 00300002
    where R11 , R5 and n are as defined earlier and Z represents hydroxy or a leaving group L1 such as chloride, bromide, p-toluenesulfonate, methanesulfonate. trifluoromethanesulfonate and the like.
  • The reaction of compound of (XIII) with a compound of formula (XIX) to yield a compound of formula (VI) or (IV) may be carried out using similar conditions described for the reaction of formula (XIII) with the compound of general formula (XIV).
  • The pharmaceutically acceptable salts are prepared by reacting the compound of formula (I) with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guanidine and their derivatives etc. may also be used. Alternatively, acid addition salts are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid. nitric acid. sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid. maleic acid, salicylic acid, hydroxynaphthoic acid. ascorbic acid, palmitic acid, succinic acid. benzoic acid, benzenesulfonic acid. tartaric acid and the like in solvents like ethyl acetate, ether, alcohols. acetone. THF. dioxane etc. Mixture of solvents may also be used.
  • The term neat as used in this application means the reaction is carried out without the use of a solvent.
  • The stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomeric form or by resolving the mixture of stereoisomers by conventional methods. Some of the preferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid and the like or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like.
  • Various polymorphs of compound of general formula (I) forming part of this invention may be prepared by crystallization of compound of formula (I) under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization: crystallizations at different temperatures: various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe nmr spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
  • The present invention also provides a pharmaceutical composition, containing the compounds of the general formula (I), as defined above, their tautomeric forms. their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates or mixtures thereof in combination with the usual pharmaceutically employed carriers, diluents and the like, useful for the treatment and / or prophylaxis of hyperlipidemia, hypercholesterolemia, hyperglycemia, osteoporosis, obesity, glucose intolerance, insulin resistance and also diseases or conditions in which insulin resistance is the underlying pathophysiological mechanism such as type II diabetes, impaired glucose tolerance, dyslipidaemia, hypertension, coronary heart disease and other cardiovascular disorders including atherosclerosis; insulin resistance associated with obesity and psoriasis, for treating diabetic complications and other diseases such as polycystic ovarian syndrome (PCOS), certain renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal diseases and microalbuminuria as well as certain eating disorders, as aldose reductase inhibitors and for improving cognitive functions in dementia.
  • The pharmaceutical composition may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions, suspensions and the like, may contain flavourants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. Such compositions typically contain from 1 to 20 %, preferably 1 to 10 % by weight of active compound, the remainder of the composition being pharmaceutically acceptable carriers, diluents, excipients, or solvents.
  • A typical tablet production method is exemplified below : Tablet Production Example :
  • a) 1) Active ingredient 10g
    2) Lactose 110 g
    3) Corn starch 35 g
    4) Carboxymethyl cellulose 44 g
    5) Magnesium stearate 1 g
    200 g for 1000 tablets
  • The ingredients 1 to 3 are uniformly blended with water and granulated after drying under reduced pressure. The ingredient 4 and 5 are mixed well with the granules and compressed by tabletting machine to prepare 1000 tablets each containing 10 mg of active ingredient.
    b) 1) Active ingredient 10 g
    2) Calcium phosphate 90 g
    3) Lactose 50 g
    4) Corn starch 45 g
    5) Polyvinyl pyrrolidone 3.5 g
    6) Magnesium stearate 1.5 g
    200 g for 1000 tablets
  • The ingredients 1 to 4 are uniformly moistened with an aqueous solution of ingredient 5 and granulated after drying under reduced pressure. Ingredient 6 is added and granules are compressed by a tabletting machine to prepare 1000 tablets containing 10 mg of active ingredient 1.
  • The compound of the formula (I) as defined above are clinically administered to mammals, including man, via either oral or parenteral routes. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or absorption following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally. By either route, the dosage is in the range of about 0.10 mg to about 200 mg / kg body weight of the subject per day or preferably about 0.10 mg to about 30 mg / kg body weight per day administered singly or as a divided dose. However, the optimum dosage for the individual subject being treated will be determined by the person responsible for treatment, generally smaller doses being administered initially and thereafter increments made to determine the most suitable dosage.
  • Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions. The active compound will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above. Thus, for oral administration, the compounds can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like. The pharmaceutical compositions, may, if desired, contain additional components such as flavourants. sweeteners, excipients and the like. For parenteral administration, the compounds can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil. aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or salts with base of the compounds. The injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.
  • The invention is explained in detail in the examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.
  • Preparation 1 4-[[2-Methyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]nitrobenzene:
  • Figure 00350001
  • Step A : Preparation of 4-[2-oxo-propoxy]nitrobenzene - To stirred suspension of K2CO3 (50.0 g, 0.36 mol) in dry DMF (500 mL) was added 4-nitrophenol (25.0 g, 0.18 mol) and stirred for 30 min at 25 °C. Chloroacetone (21.5 mL, 0.27 mol) was added to the reaction mixture and stirred for 24 h at 25- 30 °C. The reaction mixture was filtered through a buchner funnel. The filtrate was poured into water (500 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The crude compound was purified by column chromatography using EtOAc : Pet. ether (1 : 2) as eluent to yield the title compound (11.0 g. 31 %) as a colourless liquid.
    1H NMR (CDCl3) : δ 8.22 (d, J = 9.17 Hz. 2H), 6.95 (d, J = 9.17 Hz, 2H), 4.67 (s, 2H), 2.30 (s, 3H).
  • Step B :
  • To a stirred mixture of salicylamide (6.85 g, 50 mmol) and 4-[2-oxo-propyloxy]nitrobenzene (9.75 g, 50 mmol) in benzene (500 mL) was added piperidine (0.52 mL, 5 mmol). The reaction mixture was immersed in a pre-heated oil bath (-100 °C) and refluxed for 10 h with continuous removal of water using Dean-Stark water separator. The reaction mixture was cooled to room temperature and the precipitated brown coloured solid was filtered, washed with benzene and dried to afford the title compound (13.5 g, 86 %).
    1 H NMR (CDCl3) : δ 8.76 (bs, 1H, D2O exchangeable), 8.14 (d. J = 9.20 Hz, 2H). 7.82 (d, J = 7.50 Hz, 1H), 7.42 (t, J = 7.50 Hz, 1H), 7.06 (t, J = 7.50 Hz. 1H), 6.99 (d. J = 9.20 Hz, 2H), 6.88 (d, J = 7.50 Hz, 1H), 4.30 (d. J = 10.33 Hz. 1H), 4.14 (d. J = 10.33 Hz. 1H). 1.72 (s, 3H).
  • Preparation 2 4-[[2,3-Dimethyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy] nitrobenzene :
  • Figure 00360001
  • To a stirred mixture of 4-[[2-methyl-4-oxo-3.4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]nitrobenzene (5.0 g, 15.9 mmol) obtained in preparation 1 and K2CO3 (6.6 g, 47.7 mmol) in acetone (60 mL) was added CH3I (9.9 mL, 159 mmol) and refluxed for 12 h. The reaction mixture was cooled to room temperature, filtered through buchner funnel to remove all the inorganic salts and acetone was removed at 40°C. The residue was poured into water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The organic extracts were washed with brine. dried over anhydrous Na2SO4 and concentrated to afford the title compound (5.1 g, 98 %).
    1N NMR (CDCl3): δ 8.19 (d, J = 9.10 Hz. 2H), 7.94 (d, J = 7.50 Hz, 1H). 7.42 (t, J = 7.50 Hz, 1H), 7.11 (t, J = 7.50 Hz. 1H), 6.95 (d, J = 9.10 Hz. 2H), 6.88 (d, J = 7.50 Hz, 1H), 4.30 - 4.10 (m, 2H), 3.22 (s, 3H), 1.88 (s, 3H).
  • Preparation 3 4-[[2,3-Dimethyl-4-oxo-3,4-dihydro-(2H)-1 ,3-benzoxazine-2-yl] methoxy]aniline :
  • Figure 00360002
  • A solution of 4-[[2,3-dimethyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazinc-2-yl]methoxy] nitrobenzene (5.0 g, 15.2 mmol) obtained in preparation 2, in 1,4-dioxane (100 mL) was reduced with hydrogen in the presence of 10% palladium charcoal (500 mg) at 40 psi for 16 h. The reaction mixture was filtered through a bed of celite and washed with dioxane and evaporated to dryness under reduced pressure to yield the title compound (4.2 g, 93 %), mp : 162-164°C.
    1H NMR (CDCl3): δ 7.92 (d, J = 7.3 5 Hz, 1H), 7.40 (t, J = 7.35 5Hz, 1H), 7.05 (t, J = 7.35 Hz, 1H), 6.87 (d, J = 7.35 Hz, 1H), 6.68 - 6.52 (m, 4H), 4.12 - 3.98 (m. 2H), 3.18 (s, 3H), 1.8 (s, 3H).
  • Preparation 4 Ethyl 2-bromo-3-[4-[[2,3-dimethyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy] phenyl]propionate ;
  • Figure 00370001
  • To a stirred solution of 4-[[2,3-dimethyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]aniline (2.5 g, 8.4 mmol) obtained from preparation 3, in acetone (20 mL) was added aq HBr (6 mL. 33.6 mmol, 47 %) and stirred for 20 min at 0 - 10°C. A solution of NaNO2 (638 mg, 9.24 mmol) in water (1.5 mL) was added slowly dropwise at 0 - 10 °C and stirred further for 30 min at 0 - 15 °C. To the reaction mixture. ethyl acrylate (5.5 mL, 50.4 mmol) was added and allowed to warm to 30 °C. Catalytic amount of cuprous oxide (200 mg) was added in one portion and the reaction mixture was stirred further for 1h at 30 °C. Acetone was removed under reduced pressure. The resultant residue was extracted with ethyl acetate (3 x 25 mL). The combined organic layers were washed with ethyl acetate (3 x 25 mL), dilute NH3 solution, water, followed by brine, dried over anhydrous Na2SO4. The solvent was evaporated under reduced pressure and the residue was purified by flash chromatography using EtOAc : pet. ether (4 : 6) as an eluent to yield the title compound (1.5 g, 39 %).
    1 H NMR (CDCl3): δ 7.95 (d. J = 7.50 Hz, 1H), 7.41 (t, J = 7.50 Hz, 1H), 7.09 (d, J = 8.30 Hz, 2H), 7.05 (d, J = 7.50 Hz, I H), 6.85 (d, J = 7.50 Hz, 1H), 6.71 (d, J = 8.30 Hz, 2H), 4.29 (dd, J = 8.50, 7.05 Hz, 1H), 4.23 - 4.02 (m, 4H), 3.38 (dd, J = 13.70, 7.05 Hz, 1H), 3.20 (s, 3H), 3.15 (dd, J = 13.70, 8.50 Hz, 1H), 1.88 (s, 3H), 1.22 (t, J = 7.30 Hz. 3H).
  • Preparation 5 4-[(2,2-diethoxy]ethoxy]benzaldehyde :
  • Figure 00380001
  • To a stirred suspension of sodium hydride (2.5 g, 100 mmol, 98 %) in DMF (100 mL) was added a solution of 4-hydroxy benzaldehyde (10.0 g, 82 mmol) in DMF (100 mL) slowly dropwise at 25 - 30 °C and stirred for 30 min at 25 - 30 °C. 2,2-diethoxy-1-bromoethane (19.7 g, 100 mmol) was added to the reaction mixture. The reaction mixture was immersed in a preheated oil bath at 60 °C. and stirring was continued for 48 h at 60°C. The reaction mixture was cooled to room temperature, quenched with water (200 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The crude compound was purified by column chromatography using EtOAc : pet. ether (1 : 2) as eluent to yield the title compound (12.65 g, 58 %) as a brown coloured liquid.
    1H NMR (CDCl3) : δ 9.88 (s, 1H), 7.82 (d, J = 8.63 Hz, 2H), 7.02 (d, J = 8.63 Hz, 2H), 4.85 (t, J = 5.17 Hz, 1H), 4.08 (d, J = 7.17 Hz, 2H), 3.88 - 3.50 (m, 4H), 1.24 (t, J = 7.03 Hz, 6H).
  • Example 1 5-[4-[(2,2-Diethoxy)ethoxy]phenyl methylene]thiazolidin-2,4-dione :
  • Figure 00390001
  • A mixture of 4-[(2,2-diethoxy]ethoxy]benzaldehyde (10.6 g, 44.53 mmol), thiazolidin-2,4-dione (5.21 g, 44.53 mmol), benzoic acid (0.70 g, 5.78 mmol) and piperidine (0.64 mL, 6.7 mmol) in toluene (150 mL) was refluxed for 2h with continuous removal of water. The reaction mixture was cooled to room temperature and diluted with EtOAc (150 ml). The mixture was washed with water. brine, dried over anhydrous Na2SO4 and concentrated. The crude compound was purified by column chromatography using EtOAc : pet. ether (1:2) as eluent to afford the title compound (12.54 g, 70 %) as a brown coloured liquid.
    1H NMR (CDCl3) : δ 8.70 (bs, 1H, D2O exchangeable), 7.80 (s, 1H), 7.45 (d, J = 8.72 Hz, 2H), 7.02 (d, J = 8.72 Hz, 2H), 4.87 (t, J = 5.21 Hz, 1H), 4.08 (d, J = 5.21 Hz.2H), 3.90 - 3.52 (m, 4H), 1.26 (t, J = 7.02 Hz, 6H).
  • Example 2 5-[4-[(2,2-Diethoxy)ethoxy]phenyl methyl]thiazolidin-2,4-dione :
  • Figure 00390002
  • A solution of 5-[4-[(2,2-diethoxy)ethoxy]phenyl methylene]thiazolidin-2,4-dione (8.0 g, 23.7 mmol) obtained in example 1, in 1,4-dioxane (100 mL) was reduced with hydrogen in the presence of 10 % palladium on charcoal (16.0 g) at 60 psi for 60 h. The mixture was filtered through a bed of celite. The filtrate was evaporated to dryness under reduced pressure: purified by column chromatography using EtOAc : pet. ether (1 : 1) as an eluent to afford the title compound (8.04 g, 67 %) as a colourless liquid.
    1H NMR (CDCl3) : δ 8.75 (bs, 1H, D2O exchangeable), 7.14 (d, J = 8.63 Hz, 2H), 6.87 (d, J = 8.63 Hz, 2H), 4.84 (t, J = 5.25 Hz, 1H), 4.49 (dd, J = 9.46, 3.83 Hz, 1H), 3.99 (d, J = 5.25 Hz, 2H), 3.88 - 3.52 (m. 4H), 3.45 (dd. J = 14.11, 3.83 Hz, I H), 3.10 (dd, J = 14.11, 9.46 Hz, 1H), 1.25 (t, J = 7.03 Hz, 6H).
  • Example 3 5-[4-1[[4-Oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl]thiazotidin-2,4-dione :
  • Figure 00400001
  • To a stirred solution of polyphosphonate ethyl ester (PPE) (3.15 g, 7.29 mmol) in chloroform (4.0 mL) was added salicylamide (0.5 g, 3.65 mmol) followed by addition of a solution of 5-[4-[(2,2-diethoxy)ethoxy]phenyl methyl]thiazolidin-2,4-dione (1.36 g, 4.0 mmol) obtained in example 2, in chloroform (10 mL) dropwise at 25 - 30 °C. The reaction mixture was immersed in a preheated oil bath and refluxed for 3 h. The reaction mixture was cooled to room temperature and CHCl3 was removed under reduced pressure. To the resultant residue aq. sat. NaHCO3 solution (25 mL) was added and stirred for 30 min. at 25 - 30 °C. The precipitated brown coloured solid was filtered and purified by column chromatography EtOAc : pet. ether ( 1:1 ) to yield the title compound (1.15 g, 81 %). mp: 134 °C - 138 °C.
    1H NMR (CDCl3) : δ 11.80 (bs, 1H, D2O exchangeble), 8.40 (bs, 1H, D2O exchangeable), 7.9 (d, J = 7.50 Hz, 1H), 7.15 (d. J = 8.30 Hz, 2H), 7.05 (t. J = 7.50 Hz. 1H), 6.90 (d, J = 7.50 Hz, 1H), 6.80 (d, J = 8.30 Hz, 2H), 5.80 (t, J = 5.30 Hz. 1H), 4.42 (dd. J = 9.50, 3.80 Hz. 1H), 4.30 - 4.10 (m. 2H), 3.34 (dd, J = 1=1.10. 3.80 Hz. 1H), 3.02 (dd, J = 14.10, 9.50 Hz, 1H).
  • Example 4 5-[4-[[3-Methyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl] thiazolidin-2,4-dione :
  • Figure 00410001
  • The title compound (0.4 g, 60 %) was obtained from N-methyl salicylamide (250 mg, 1.66 mmol), 5-[4-[(2.2-diethoxy)ethoxy]phenyl methyl]thiazolidin-2.4-dione (620 mg, 1.82 mmol) obtained in example 2 and PPE (1.40 g, 3.32 mmol), by a similar procedure to that described in example 3. mp : 187°C.
    1H NMR (CDCl3) : δ 8.23 (bs, 1H, D2O, exchangeable), 7.95 (d, J = 7.50 Hz, 1H), 7.43 (t, J = 7.50 Hz, 1H), 7.12 (d, J = 8.54 Hz. 2H), 7.08 (t, J = 7.50 Hz, I H), 6.93 (d, J = 7.50 Hz, 1H), 6.77 (d, J = 8.54 Hz, 2H), 5.62 (t, J = 5.39 Hz. 1H). 4.48 (dd, J = 9.04, 3.74 Hz, 1H), 4.32 - 4.08 (m. 2H), 3.45 (dd, J =14.05, 3.74 Hz, 1H), 3.21 (d. J = 3.83 Hz. 3H), 3.10 (dd. J = 14.05. 9.04 Hz. 1H).
  • Example 5 5-[4-[[3-Ethyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl] thiazolidin-2,4-dione :
  • Figure 00410002
  • The title compound (0.51 g. 69 %) was obtained from N-ethyl salicylamide (300 mg, 1.82 mmol) and 5-[4-[(2,2-diethoxy)ethoxy]phenyl methyl]thiazolidin-2,4-dione (677 mg, 1.99 mmol) obtained in example 2 and PPE (1.57 g, 3.64 mmol) by a similar procedure to that described in example 3. mp : 70-72°C.
    1H NMR (CDCl3) : δ 8.10 (bs, 1H, D2O exchangeable), 7.96 (d, J = 7.50 Hz, 1H), 7.41 (t. J = 7.50 Hz, 1H), 7.11 (d, J = 8.40 Hz. 2H), 7.05 (t, J = 7.50 Hz, 1H), 6.91 (d, J = 7.50 Hz, 1H), 6.72 (d, J = 8.40 Hz, 2H), 5.62 (t, J = 5.40 Hz. 1H), 4.48 (dd, J = 9.03, 3.87 Hz, 1H), 4.42 - 3.90 (m, 3H), 3.50 - 3.02 (m, 3H), 1.28 (t, J = 7.05 Hz, 3H),
  • Example 6 Step A: 5-[4-[[2,3-Dimethyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazin-2-yl]methoxy]phenyl methyl]-2-iminothiazolidin-4-one :
  • Figure 00420001
  • A mixture of ethyl 2-bromo-3-[4-[[2,3-dimethyl-4-oxo-3.4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl]propionate (1.5 g, 3.25 mmol) obtained in preparation 4, fused sodium acetate (884 mg, 6.5 mmol) and thiourea (493 mg, 6.5 mmol) in ethanol (12 mL) was refluxed for 12 h. The reaction mixture was cooled to room temperature and ethanol was removed under reduced pressure. The resultant residue was diluted with ethyl acetate and washed with water. Ethyl acetate layer was dried over anhydrous Na2SO4 and concentrated. The crude compound was chromatographed on silica gel using EtOAc : pet. ether (1 : 1) as eluent to obtain the title compound (1.1 g, 82 %).
    1H NMR (DMSO-d6) : δ 7.91 (d, J = 7.50 Hz, 1H), 7.40 (t. J = 7.50 Hz, 1H), 7.05 (d, J = 8.30 Hz, 2H), 7.02 (t, J = 7.50 Hz, 1H), 6.88 (d, J = 7.50 Hz, 1H), 6.70 (d, J = 8.30 Hz, 2H), 4.41 (dd, J = 9.50, 3.75 Hz, 1H), 4.11 (s. 2H), 3.45 (dd, J = 14.12, 3.75 Hz. 1H), 3.18 (s, 3H), 2.92 (dd, J = 14.12, 9.50 Hz, 1H), 1.82 (s. 3H).
  • Step B : 5-[4-[2,3-Dimethyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxaxine-2-yl]methoxy]phenyl methyl] thiazolidin-2,4-dione :
  • Figure 00430001
  • To a stirred solution of the compound (1 g. 2.43 mmol) obtained above in ethanol (20 mL) was added 2N HCl (5 mL) and refluxed for 12h. The reaction mixture was cooled to room temperature and ethanol was removed under reduced pressure. The aqueous layer was neutralised with saturated aqueous NaHCO3 solution and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The crude compound was chromatographed on silica gel using EtOAc : pet. ether (1:1) as eluent to yield the title compound (450 mg, 45 %). mp : 58 - 60 °C.
    1H NMR (CDCl3): δ 7.92 (d, J = 8.30 Hz, 1H), 7.42 (t, J = 8.30 Hz, 1H), 7.12 (d, J = 8.50 Hz, 2H), 7.06 (t, J = 8.30 Hz, 1H), 6.87 (d, J = 8.30 Hz, 1H), 6.76 (d. J = 8.50 Hz, 2H). 4.50 (s, 2H), 4.48 (dd, J = 9.30, 3.90 Hz, 1H), 3.40 (dd, J = 14.11, 3.90 Hz, 1H), 3.18 (d, J = 4.24 Hz. 3H), 3.08 (dd. J = 14.11, 8.30 Hz, 1H), 1.85 (s, 3H).
  • Example 7 5-[4-[[4-Oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methy]thiazolidin-2,4-dione, sodium Salt :
  • Figure 00430002
  • To a stirred suspension of 5-[4-[[4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl]thiazolidin-2,4-dione (250 mg, 0.65 mmol) obtained from example 3, in methanol (4 mL) was added a solution of sodium methoxide (55 mg, 1.0 mmol) in methanol (1 mL) dropwise at 25 - 30 °C. During this period the suspension slowly dissolved completely and a white solid precipitated out which was stirred further for 1h. The solid was filtered and washed with methanol (2 mL) and dried to afford the title compound (250 mg, 95 %). mp : 280 °C.
    1 H NMR (DMSO-d6) : δ 7.70 (d, J = 7.50 Hz, 1H), 7.35 (t, J = 7.50 Hz, 1H), 7.10 (d, J = 8.30 Hz, 2H), 7.00 (d, J = 7.50 Hz, 1H), 6.85 (d, J = 7.50 Hz, 1H), 6.75 (d, J = 8.30 Hz, 2H), 5.70 (t, J = 5.30 Hz, 1H), 4.05 (dd, J = 8.95, 3.90 Hz, 1H), 3.90 - 3.80 (m, 2H), 3.23 (dd, J = 13.80, 3.90 Hz, 1H), 2.65 (dd, J = 13.80. 8.95 Hz, 1H).
  • Example 8 5-[4-[[3-Methyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl] thiazolidin-2,4-dione, sodium salt :
  • Figure 00440001
  • The title compound (136 mg, 81 %) was obtained from 5-[4-[[3-methyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-y]methoxy]phenyl methyl]thiazolidin-2,4-dione (150 mg, 0.39 mmol) obtained in example 4, by a similar procedure to that described in example 7. mp: 205 - 298°C.
    1H NMR (CDCl3+DMSO-d6) : δ 7.78 (d, J = 7.50 Hz. 1H), 7.48 (t, J = 7.50 Hz, 1H), 7.35 - 6.95 (m, 4H), 6.75 (d, J = 8.30 Hz, 2H), 5.86 (t, J = 4.98 Hz, 1H), 4.20 (d. J = 4.98 Hz, 2H), 4.06 (dd, J = 10.38, 3.23 Hz, 1H), 3.24 (dd. J = 13.70. 3.23 Hz, 1H), 3.09 (s, 3H), 2.64 (dd, J = 13.70, 10.38 Hz, 1H).
  • Example 9 5-[4-[[1,3-Dimethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy] phenyl methylene] thiazolidin-2,4-dione :
  • Figure 00450001
  • The title compound was obtained from N,N'-dimethylanthranilamide (500 mg, 3.04 mmol), 5-[4-[(2,2-diethoxy)ethoxy]phenyl methylene]thiazolidin-2.4-dione (1.13 g, 3.35 mmol) obtained in example 1 and PPE (2.63 g, 6.10 mmol) by a similar procedure to that described in example 3. mp : 236 - 240°C.
    1H NMR (DMSO-d6) : δ 7.72 (d. J = 7.47 Hz. 1H), 7.57 (s. 1H), 7.50 - 7.30 (m, 3H), 6.96 (d, J = 8.30 Hz, 2H), 6.90 - 6.60 (m, 2H), 5.23 (t, J = 5.30 Hz. 1H), 4.22 (d, J = 5.30 Hz, 2H), 3.14 (s, 3H), 3.07 (s, 3H).
  • Example 10 5-[4-[[3-Methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methylene]thiazolidin-2,4,dione :
  • Figure 00450002
  • The title compound (800 mg, 65 %) was obtained from N-methyl anthranilamide (500 mg, 3.3 mmol), 5-[4-[(2.2-diethoxy)ethoxy]phenyl methylene]thiazolidin-2.4-dione (1.23 g, 3.66 mmol) obtained from example 2 and PPE (2.85 g, 6.6 mmol) by a similar procedure to that described in example 3. mp : 66 - 68°C.
    1H NMR (DMSO-d6) : δ 7.67 (s, 1H), 7.63 (d. J = 7.80 Hz, 1H), 7.51 (d, J = 8.60 Hz, 2H), 7.23 (t, J = 7.80 Hz, 1H), 7.03 (d, J = 8.60 Hz. 2H), 6.80 - 6.60 (m, 2H), 5.12 (t, J = 5.30 Hz, 1H), 4.14 (d. J = 5.30 Hz, 2H), 3.08 (s. 3H).
  • Example 11 5-[4-[[1,3-Dimethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl] methoxy] phenyl methyl) thiazolidin-2,4-dione:
  • Figure 00460001
  • Method A
  • The title compound (3.84 g, 82 %) was obtained from N, N'-methylanthranilamide (1.87 g, 11.4 mmol), 5-[4-[(2.2-diethoxy)ethoxy]phenyl methyl]thiazolidin-2.4-dione (2.0 g, 5.8 mmol) obtained in example 2 and PPE (9.86 g, 22.8 mmol) by a similar procedure to that described in example 3. mp : 201.9°C.
  • Method B :
  • The title compound (340 mg, 64 %) was obtained from 5-[4-[[1,3-dimethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy] phenyl methylene]thiazolidin-2.4-dione (500 mg) obtained in example 9 by a similar procedure to that described in example 2.
    1H NMR (CDCl3) : δ 8.76 (bs, 1H, D2O exchangeable), 7.94 (d, J = 7.50 Hz, 1H), 7.38 (t, J = 7.50 Hz, 1H), 7.10 (d, J = 8.30 Hz, 2H), 6.86 (t, J = 7.50 Hz. 1H), 6.71 (d. J = 8.30 Hz, 2H), 6.62 (d, J = 7.50 Hz, 1H), 4.87 (t, J = 5.81 Hz, 1H), 4.45 (dd, J = 9.04, 3.83 Hz, 1H), 4.20 - 4.00 (m, 2H), 3.38 (dd, J = 14.02, 3.83 Hz. 1H), 3.23 (s. 3H), 3.12 (s, 3H). 3.10 (dd, J = 14.02, 9.04 Hz. 1H).
  • Example 12 5-[4-[[3-Methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione :
  • Figure 00470001
  • Method A :
  • The title compound (0.96 g, 95 %) was prepared from 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl methylene]thiazolidin-2,4-dione (1.0 g) (preparation described in copending US application numbers 08/777,627 and 08/884.816), by a similar procedure to that described in example 2.
  • Method B :
  • The title compound (350 mg, 44 %) was obtained from N-methyl anthranilamide (272 mg, 2.0 mmol) and 5-[4-[(2,2-diethoxy)ethoxy]phenyl methyl]thiazolidin-2,4-dione (746 mg, 2.2 mmol) obtained from example 2 and PPE (1.73 g, 4.0 mmol) by a similar procedure to that described in example 3. mp : 86 - 90 °C.
  • Method C :
  • The title compound (480 mg, 96 %) was prepared from 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl methyl]thiazolidin-2,4-dione (500 mg) (preparation described in copending US application numbers 08/777,627 and 08/884,816), by a similar procedure to that described in example 2.
  • Method D :
  • The title compound (440 mg, 88 %) was prepared from 5-[4-[[3-methyl-4-oxo-1,2,3,4-dihydro-2-quinazolinyl]methoxy]phenyl methylene]thiazolidin-2,4-dione (500 mg) obtained in example 10, by a similar procedure to that described in example 2.
    1H NMR (CDCl3) : δ 8.23 (bs, 1H, D2O exchangeable), 7.95 (d, J = 7.50 Hz, 1H), 7.43 (t. J = 7.50 Hz, 1H), 7.12 (d, J = 8.54 Hz, 2H), 7.08 (t, J = 7.50 Hz, 1H), 6.93 (d. J = 7.50 Hz, 1H), 6.77 (d, J = 8.54 Hz. 2H), 5.62 (t, J = 5.39 Hz, 1H), 4.48 (dd. J = 9.04. 3.74 Hz, 1H), 4.32 - 4.08 (m, 2H). 3.45 (dd. J = 14.05, 3.74 Hz, 1H), 3.20 (d, J = 3.83 Hz, 3H), 3.10 (dd, J = 14.05, 9.04 Hz. 1H).
  • Example 13 5-[4-[[3-Ethyl-1-methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione :
  • Figure 00480001
  • The title compound (1,6 g, 65 %) was obtained from 2-(N-methyl)amino-N-ethyl benzamide (1.08 g, 6.06 mmol) and 5-[4-[(2,2-diethoxy)ethoxy]phenyl methyl]thiazolidin-2,4-dione (2.26 g, 6.68 mmol) obtained in example 2 and PPE (5.23 g, 12.13 mmol) by a similar procedure to that described in example 3. mp : 72 - 74 °C.
    1H NMR (CDCl3) : δ 11.99 (bs, 1H, D2O exchangeable), 7.69 (d, J = 7.50 Hz, 1H). 7.36 (t, J = 7.50 Hz, 1H), 7.09 (d, J = 8.30 Hz, 2H), 6.78 (t, J = 7.50 Hz, 1H), 6.76 (d, J = 8.30 Hz. 2H), 6.68 (d, J = 7.50 Hz, 1H), 5.18 (t, J = 5.30 Hz, 1H), 4.84 (dd, J = 8.62.4.47 Hz, 1H), 4.05 (q, J = 7.05 Hz, 2H), 4.12 - 3.80 (m, 2H), 3.36 (dd, J = 14.05, 4.47 Hz, 1H), 3.06 (s, 3H), 3.13 (dd, J = 14.05, 8.62 Hz, 1H), 1.18 (t, J = 7.05 Hz, 3H).
  • Example 14 5-[4-[[1-Methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione :
  • Figure 00480002
  • The title compound (450 mg, 23 %) was obtained from 2-(N-methyl)amino benzamide (750 mg, 5.0 mmol) and 5-[4-[(2,2-diethoxy)ethoxy]phenyl methyl]thiazolidin-2,4-dione (1.87 g, 5.51 mmol) obtained in example 2 and PPE (4.33 g, 10.02 mmol) by a similar procedure to that described in example 3. mp : 108 - 110°C.
    1H NMR (CDCl3) : δ 10.10 (bs, 1H, D2O exchangeable), 7.93 (d, J = 7.50 Hz, 1H), 7.42 (t, J = 7.50 Hz, 1H), 7.09 (d, J = 8.53 Hz, 2H), 6.84 (t, J = 7.50 Hz, 1H), 6.73 (d, J = 8.53 Hz, 2H), 6.64 (d, J = 7.50 Hz, 1H), 4.98 (t, J = 4.56 Hz, 1H), 4.43 (dd, J = 8.90. 3.97 Hz, 1H), 4.20 - 3.82 (m, 2H), 3.37 (dd, J = 14.11, 3.97 Hz, 1H), 3.12 (dd, J = 14.11, 8.90 Hz, 1H), 3.10 (s, 3H).
  • Example 15 5-[4-[[1,3-Dimethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione, sodium salt :
  • Figure 00490001
  • The title compound (150 mg, 95 %) was obtained from 5-[4-[[1,3-dimethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl]thiazolidin-2,4-dione (150 mg, 0.36 mmol) obtained in example 11, by a similar procedure described in example 7. mp : 281 - 237°C.
    1H NMR (CDCl3) : δ 7.72 (d, J = 7.50 Hz, 1H), 7.40 (t, J = 7.50 Hz, 1H), 7.10 (d, J = 8.30 Hz, 2H), 6.90 - 6.66 (m, 4H), 5.20 (t, J = 5.30 Hz, 1H), 4.20 - 4.05 (m, 3H), 3.32 (dd, J = 13.53, 3.23 Hz, 1H), 3.13 (s, 3H), 3.07 (s, 3H), 2.62 (dd, J = 13.52, 10.70 Hz. 1H).
  • Example 16 5-[4-[[4-Oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl]thiazolidin-2,4-dione
  • Figure 00500001
  • The title compound (0.42 g, 50%) was obtained from anthranilamide (0.3 g, 2.2 mmol) and 5-[4-[(2,2-diethoxy]ethoxy]phenyl methyl]thiazolidin-2,4-dione (0.82 g, 2.42 mmol) obtained in example 2 and PPE (1.91 g, 4.4 mmol) by a similar procedure to that described in example 3. m.p : 81-83 °C
    1H NMR (CDCl3) : δ 8.59 (bs, 1H, D2O exchangeable), 7.89, (d, J = 7.70 Hz, 1H), 7.35 (t, J = 7.50 Hz, 1H), 7.15 (d, J = 8.62 Hz, 2H), 6.95 - 6.75 (m, 3H), 6.69 (d, J = 7.50 Hz, 1H}, 5.20 (t, J = 5.70 Hz, 1H), 4.65 (bs, 1H, D2O exchangeable), 4.49 (dd, J = 9.03, 4.06 Hz, 1H), 4.20 - 4.10 (m, 1H), 4.10 - 3.92 (m, 1H), 3.40 (dd, J = 14.12, 4.06 Hz, 1H), 3.18 (dd, J = 14.12, 9.03 Hz. 1H).
  • Example 17 5-[4-[[1,3-Diethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl] methoxy] phenyl methyl]thiazolidin-2,4-dione
  • Figure 00500002
  • The title compound (0.4 g, 53 %) was obtained from N, N'-diethylanthranilamide (0.32 g, 1.66 mmol) and 5-[4-[(2,2-diethoxy]ethoxy]phenyl methyl]thiazolidin-2.4-dione (0.62 g, 1.83 mmol) obtained in example 2 and PPE (1,44 g, 3.37 mmol) by a similar procedure to that described in example 3. m.p : 74-76 °C
    1H NMR (CDCl3) : δ 8.60 (bs, 1H, D2O exchangeable), 7.95, (d, J = 7.50 Hz, 1H), 7.36 (t, J = 7.50 Hz, 1H), 7.09 (d, J = 8.60 Hz, 2H), 6.86 (t, J = 7.57 Hz, 1H), 6.75 (d, J = 7.50 Hz, 1H), 6,71 (d, J = 8.60 Hz, 2H), 4.92 (t, J = 5,81 Hz, 1H), 4.46 (dd, J = 9.13.3.73 Hz, 1H), 4.20 - 3.90 (m, 3H), 3.90 - 3.00 (m, 5H), 1.45 - 1.15 (m, 6H).
  • Example 18 5-[4-[[1-Ethyl-3-methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione
  • Figure 00510001
  • The title compound (575 mg, 52 %) was obtained from N-ethyl-N'-methylanthranilamide (460 mg, 2.58 mmol) and 5-[4-[(2,2-diethoxy]ethoxy]phenyl methyl]thiazolidin-2,4-dione (963 mg, 2.8 mmol) obtained in example 2 and PPE (1.91 g, 4.4 mmol) by a similar procedure to that described in example 3. m.p : 165 °C.
    1H NMR (CDCl3) : δ 8.30 (bs, 1H, D2O exchangeable), 7.96 (d, J = 7.50 Hz, 1H), 7.38 (t, J = 7.50 Hz, I H), 7.11 (d, J = 8.50 Hz, 2H), 6.88 (t, J = 7.50 Hz, 1H), 6.76 (d, J = 7.50 Hz, 1H), 6.72 (d, J = 8.50 Hz, 2H), 4.89 (t, J = 5.80 Hz, 1H), 4.47 (dd, J = 8.36, 3.78 Hz, 1H), 4.10 - 3.95 (m, 2H), 3.70 - 3.50 (m, 1H), 3.50 - 3.30 (m, 2H), 3.24 (d, J = 3.72, 3H), 3.20 - 3.00 (m, 1H), 1.30 (t, J = 7.06 Hz, 3H).
  • Example 19 5-[4-[[1-Ethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione
  • Figure 00520001
  • The title compound (240 mg, 43 %) was obtained from N-ethyl anthranilamide (300 mg, 1.83 mmol) and 5-[4-[(2,2-diethoxy]ethoxy]phenyl methyl]thiazolidin-2,4-dione (680 mg, 2.0 mmol) obtained in example 2 and PPE (1.58 g, 3.65 mmol) by a similar procedure to that described in example 3. m.p : 77 - 79 °C.
    1H NMR (CDCl3) : δ 9.40 (bs, 1H, D2O exchangeable), 7.95 (d, J = 7.50 Hz, 1H), 7.39 (t, J = 7.50 Hz, 1H), 7.09 (d, J = 8.50 Hz, 2H), 6.95 - 6.65 (m, 4H), 4.99 (t, J = 5.70 Hz, 1H), 4.44 (dd, J = 8.30, 3.00 Hz, 1H), 4.15 - 3.90 (m, 2H), 3.75 - 3.50 (m. 1H), 3.50 - 3.25 (m, 2H), 3.20 - 3.00 (m, 1H), 1.30. (t, J = 7.48 Hz, 3H).
  • Mutation in colonies of laboratory animals and different sensitivities to dietary regimens have made the development of animal models with non-insulin dependent diabetes associated with obesity and insulin resistance possible. Genetic models such as db/db and ob/ob (See Diabetes, (1982) 31(1) : 1- 6) in mice and fa/fa and zucker rats have been developed by the various laboratories for understanding the pathophysiology of disease and testing the efficacy of new antidiabetic compounds (Diabetes, (1983) 32: 830-838 ; Annu. Rep. Sankyo Res. Lab. (1994) 46 : 1-57). The homozygous animals, C57 BL/KsJ-db/db mice developed by Jackson Laboratory, US, are obese. hyperglycemic, hyperinsulinemic and insulin resistant (J. Clin. Invest., (1990) 85 : 962-967), whereas heterozygous are lean and normoglycemic. In db/db model, mouse progressively develops insulinopenia with age, a feature commonly observed in late stages of human type II diabetes when blood sugar levels are insufficiently controlled. The state of pancreas and its course vary according to the models. Since this model resembles that of type II diabetes mellitus, the compounds of the present invention were tested for blood sugar and triglycerides lowering activities.
  • The compounds of the present invention showed blood sugar and triglycerides lowering activities through improved insulin resistance. This was demonstrated by the following in vivo experiments.
  • Male C57BL/KsJ-db/db mice of 8 to 14 weeks age, having body weight range of 35 to 60 grams, procured from the Jackson Laboraotory, USA, were used in the experiment. The mice were provided with standard feed (National Institute of Nutrition, Hyderabad, India) and acidified water, ad libitum. The animals having more than 300 mg / dl blood sugar were used for testing. The number of animals in each group was 4.
  • The random blood sugar and triglyceride levels were measured by collecting blood (100 µl) through orbital sinus, using heparinised capillary in tubes containing EDTA which was centrifuged to obtain plasma. The plasma glucose and triglycerides levels were measured spectrometrically, by glucose oxidase and glycerol-3-PO4 oxidase/peroxidase enzyme (Dr. Reddy's Lab. Diagnostic Division Kits, Hyderabad, India) methods respectively. On 6th day the blood samples were collected one hour after administration of test compounds / vehicle for assessing the biological activity.
  • Test compounds were suspended on 0.25 % carboxymethyl cellulose and administered to test group at a dose of 1 mg to 100 mg / kg through oral gavage daily for 6 days. The control group received vehicle (dose 10 ml / kg). Troglitazone (100 mg / kg, daily dose) was used as a standard drug which showed 28 % reduction in random blood sugar level on 6th day.
  • The blood sugar and triglycerides lowering activities of the test compound was calculated according to the formula : Blood sugar / triglycerides lowering activity (%) = 1 - DT/DCTC/ZC X 100 ZC = Zero day control group value
    DC = Zero day treated group value
    TC = Control group value on test day
    DT = Treated group value on the test day
    No adverse effects were observed for any of the mentioned compounds of invention in the above test.
    The compounds of the present invention also showed cholesterol lowering activity in the experimental animals used.
    Compound Dose (mg/kg/day) Maximum reduction in blood glucose level (%) Triglyceride lowering (%)
    Example 12 3 55 35
    Example 11 1 34 28
    Example 4 10 48 42
    Example 3 10 41 48
    The experimental results from the db/db mice suggest that the novel compounds of the present invention also possess therapeutic utility as a prophylactic or regular treatment for obesity, cardiovascular disorders such as hypertension, hyperlipidaemia and other diseases; as it is known from the literature that such diseases are interrelated to each other.

Claims (16)

  1. A compound of formula (I)
    Figure 00550001
    its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates, wherein X represents O or S; R1, R2, R3, and R4 are the same or different and represent hydrogen, halogen, hydroxy, cyano, or nitro, or optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkyloxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, aryloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylamino, arylamino, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, thioalkyl alkylthio, acyl, acylamino, aryloxycarbonylamino, aralkoxycarbonylamino, alkoxycarbonylamino, carboxylic acid or its amides optionally substituted by an alkyl or phenyl group, acyloxy, sulfonic acid or its amides optionally substituted by an alkyl or haloalkyl group, wherein when R1, R2; R3, or R4 are substituted, the substituent is selected from halogen, hydroxy, cyano, nitro, alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, acyloxy, hydroxyalkyl, amino, acylamino, arylamino, aminoalkyl, aryloxy, alkoxycarbonyl, alkylamino, alkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its amides selected from CONH2, CONHMe, CONMe2, CONHEt, CONEt2, or CONHPh, or sulfonic acid or its derivatives selected from SO2NH2, SO2NHMe, SO2NMe2 or SO2NHCF3; W represents O, S or a group NR9; R6 and R9 are the same or different and represent hydrogen or optionally substituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, hydroxyalkyl, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, alkylthio, or thioalkyl groups wherein when R6, R9 or both are substituted, the substituent is selected from halogen, hydroxy, acyl, acyloxy or amino; R5 represents hydrogen, hydroxy or halogen or optionally substituted alkyl, aryl, heteroaryl, acyl, alkoxy, aralkyl, or aralkoxy wherein when R5 is substituted, the substituent is selected from hydroxy, halogen, linear or branched (C1-C6)alkyl, acyl or acyloxy, n is an integer ranging from 1- 4; Ar represents an optionally substituted divalent aromatic or heterocyclic group wherein when Ar is substituted, the substituent is selected from linear or branched (C1-C6)alkyl, (C1-C3) alkoxy, halogen, acyl, amino, acylamino, thio; or carboxylic acid or its amides selected from CONH2, CONHMe, CONMe2, CONHEt, CONEt2, or CONHPh, or sulfonic acid or its derivatives selected from SO2NH2, SO2NHMe, SO2NMe2 or SO2NHCF3; R7 and R8 are the same or different and represent hydrogen, halogen, hydroxy, or alkyl optionally substituted by halogen, methyl or oxo group or aralkyl optionally substituted by halogen, methoxy or methyl group, or together form a bond, and B represents an oxygen atom or a sulfur atom
  2. A compound as claimed in claim 1, wherein Ar represents substituted or unsubstituted divalent phenylene, naphthylene, pyridyl, quinolinyl, benzofuryl, dihydrobenzofuryl, benzopyranyl, indolyl, indolinyl, azaindolyl, azaindolinyl, pyrazolyl, benzothiazolyl or benzoxazolyl
  3. An intermediate of formula (III)
    Figure 00560001
    wherein X, R1, R2, R3, R4, R5, R6, W and n are as defined in claim 1, Ar is as defined in claim 1 or 2, and G represents CHO, -NH2 or -CH2CH(J)-COOR where J represents a halogen atom and R represents hydrogen or (C1-C6)alkyl group.
  4. A process for the preparation of the intermediate of formula (III) as defined in claim 3,which comprises:
    a) reacting a compound of formula (IV)
    Figure 00570001
    wherein, R1, R2, R3, R4, R5, R6, X, W, and n are as defined in claim 1, with a compound of formula (V) L1―Ar―G where L1 is a halogen atom, G is a CHO group and Ar is as defined in claim 1 or 2; or
    b) reacting a compound of formula (VI)
    Figure 00580001
    where R1, R2, R3, R4, R5, R6, X, W, and n are as defined in claim 1, and L2 is a halogen atom or a leaving group with a compound of formula (VII) HO―Ar―G where G is a CHO group and Ar is as defined in claim 1 or 2; or
    c) reacting a compound of formula (IV)
    Figure 00580002
    wherein, R1, R2, R3, R4, R3, R6, X, W, and n are as defined in claim 1, with a compound of formula (VII) HO―Ar―G where G is a CHO group and Ar is as defined in claim 1 or 2; or
    d) diazotizating a compound of formula (XII)
    Figure 00580003
    wherein R1, R2, R3, R4, R5, R6, X, W, and n are as defined in claim 1 and Ar is as defined in claim 1 or 2, followed by treatment with acrylic acid ester in the presence of a hydrohalo acid and copper oxide or copper halide to yield a compound of formula (III) where R1, R2, R3, R4, R5, R6, W, X and n are as defined in claim 1 and Ar is as defined in claim 1 or 2 and G represents CH2 CH(J)-COOR group, where J is as defined in claim 3 and R represents a (C1-C12) alkyl group.
  5. A process for preparing a compound of formula (I)
    Figure 00590001
    its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates wherein X, R1, R2, R3, R4, R5, R6, R7, R8, R9, W, n, and B are as defined in claim 1, and Ar is as defined in claim 1 or 2 comprising:
    reacting a compound of formula (XIII)
    Figure 00590002
    where all symbols are as defined above, with a compound of formula (XIV)
    Figure 00590003
    where R5, R7, R8, n, Ar and B all symbols are defined above and R11 is a linear or branched (C1-C5)alkyl group to obtain a compound of formula (I) and optionally, converting the compound of formula (I) into its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, wherein the compound of formula (XIV)
    Figure 00600001
    wherein R5, R7, R8, n, and B are as defined in claim 1, Ar is as defined in claim 1 or 2 and R11 is a linear or branched (C1-C5) alkyl group is prepared by:
    a) i) reacting a compound of formula (XV)
    Figure 00600002
    where R5, R11 and n are as defined above and L1 is a leaving group, with a compound of formula (VII) HO―Ar―G where G is a CHO group and Ar is as defined in claim 1 or 2 to yield a compound of formula (XVII)
    Figure 00600003
    where all symbols are as defined above and G is a CHO group;
    ii) reacting the compound of formula (XVII) obtained in step (i) above with 2,4-thiazolidinedione or 2,4-oxazolidinedione to yield a compound of formula (XVI)
    Figure 00600004
    where all symbols are as defined above and if needed,
    iii) reducing the compound of formula (XVI) obtained in step (ii) above to yield a compound of formula (XIV) where R7 and R8 represent hydrogen atom and all other symbols are as defined above or
    b) reacting a compound of formula (XV)
    Figure 00610001
    where all symbols are as defined above and L1 is a leaving group, with a compound of formula (X)
    Figure 00620001
    where all symbols are as defined above and R10 is hydrogen atom or a nitrogen protecting group.
  6. A process for preparing a compound of formula (I)
    Figure 00620002
    its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates, wherein X, R1, R2, R3, R4, R5, R6, R7, R8, B, n and W are as defined in claim 1 and Ar is as defined in claim 1 or 2, which comprises:
    a) i) reacting the intermediate of formula (III)
    Figure 00620003
    where G represents CHO group and all other groups are as defined above, with 2,4-thiazolidinedione or 2,4-oxazolidinedione and removing the water formed during the reaction to yield a compound of formula (VIII)
    Figure 00630001
    where R1, R2, R3, R4, R5, R6, X, W, B, n, and Ar are as defined above;
    ii) reducing the compound of the formula (VIII) obtained above to obtain a compound of formula (IX)
    Figure 00630002
       wherein R1, R2, R3, R4, R5, R6, X, W, n, Ar and B are as defined above, and if needed,
    iii) converting the compounds of the formula (VIII) and (IX) obtained above into its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates; or
    b) reacting a compound of formula (XI)
    Figure 00630003
    where R1, R2, R3, R4, R5, R6, X, W, n, and Ar are as defined above, J is a halogen atom and R is a (C1-C6)alkyl group with thiourea followed by treatment with an acid; or
    c) reacting a compound of formula (IV)
    Figure 00640001
    wherein, R1, R2, R3, R4, R5, R6, X, W and n are as defined above, with a compound of formula (X)
    Figure 00650001
    where R7, R8 Ar and B are as defined above and R10 represents hydrogen atom or a nitrogen protecting group; or
    d) reacting a compound of formula (VI)
    Figure 00650002
    where R1, R2, R3, R4, R5, R6, X, W, and n are as defined above and L2 is a halogen atom or a leaving group with a compound of formula (X)
    Figure 00650003
    where R7, R8, B; Ar and R10 are as defined above.
  7. A process for preparing a compound of formula (I)
    Figure 00650004
    its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates wherein X, R1, R2, R3, R4, R5, R6, R7, R8, R9, W, n, and B are as defined in claim 1, and Ar is as defined in claim 1 or 2 comprising:
    a) reacting a compound of formula (XVI)
    Figure 00660001
    wherein R5, n, Ar and B are as defined above and R11 is a linear or branched (C1-C5) alkyl group with a compound of formula (XIII)
    Figure 00660002
    where all symbols are as defined above to yield a compound of formula (VIII)
    Figure 00660003
    where R1, R2, R3, R4, R5, R6, X, W, n, B and Ar are as defined above and optionally,
    ii) reducing the compound of formula (III) to obtain a compound of formula (IX),
    Figure 00660004
    wherein R1, R2, R3, R4, R5, R6, X, W, n, Ar and B are as above, optionally,
    iii) converting the compound of formula (VIII),
    Figure 00670001
    or (IX)
    Figure 00670002
    or both into their pharmaceutically acceptable salts, or their pharmaceutically acceptable solvates, or
    b) reacting a compound of formula (XIII)
    Figure 00670003
    where all symbols are as defined above, with a compound of formula (XIV)
    Figure 00670004
    where R5, R7, R8, n, Ar and B all symbols are defined above and R11 is a linear or branched (C1-C5)alkyl group to obtain a compound of formula (I) and optionally,
    iii) converting the compound of formula (I) into its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates.
  8. A pharmaceutical composition which comprises a compound of formula (I)
    Figure 00680001
    as defined in claim 1 or 2 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.
  9. A compound which is selected from:
    5-[4-[[4-Oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl] thiazolidin-2,4-dione;
    5-[4-[[3-Methyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl]thiazolidin-2,4-dione;
    5-[4-[[3-Ethyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl]thiazolidin-2,4-dione;
    5-[4-[2,3-Dimethyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy] phenyl methyl]thiazolidin-24-dione;
    5-[4-[[4-Oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl] thiazolidin-2, 4-dione, sodium salt;
    5-[4-[[3-Methyl-4-oxo-3,4-dihydro-(2H)-1,3-benzoxazine-2-yl]methoxy]phenyl methyl]thiazolidin-2,4-dione, sodium salt;
    5-[4-[[1,3-Dimethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methylene]thiazolidin-2,4-dione;
    5-[4-[[3-Methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methylene ]thiazolidin-2,4,dione;
    5-[4-[[ 1 ,3-Dimethyl-4-oxo-1 ,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl]thiazolidin-2,4-dione;
    5-[4-[[3- Methyl-4-oxo-1 ,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione;
    5-[4- [[3 -Ethyl- 1-methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy] phenyl methyl] thiazolidin-2,4-dione;
    5-[4-[[1-Methyl-4-oxo-1 ,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione;
    5-[4-[[ 1,3-Dimethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione, sodium salt;
    5-[4-[[4-Oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione;
    5-[4-[[1,3-Diethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione;
    5-[4-[[ 1-Ethyl-3 -methyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy] phenyl methyl] thiazolidin-2,4-dione; or
    5-[4-[[1-Ethyl-4-oxo-1,2,3,4-tetrahydro-2-quinazolinyl]methoxy]phenyl methyl] thiazolidin-2,4-dione.
  10. A pharmaceutical composition which comprises, a compound according to claim 9, as an effective ingredient and a pharmaceutically acceptable carrier, diluent or excipient.
  11. A compound according to claims 1-2 or 9 for use as a medicament.
  12. A compound according to any one of claims 1-2 or 9 for the treatment and/or prophylaxis of diabetes caused by insulin resistance or impaired glucose tolerance or complications of diabetes said diabetes caused by insulin resistance or impaired glucose tolerance.
  13. A compound according to any one of claims 1-2 or 9 for the treatment and/or prophylaxis of complications of diabetes wherein the complication is dyslipidaemia, hypertension, coronary heart disease, cardiovascular disorders, atherosclerosis, obesity, psoriasis, polycystic ovarian syndrome (PCOS), renal diseases, diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal disease, microalbuminuria or eating disorders.
  14. A compound according to any one of claims 1-2 or 9 for reducing blood glucose, triglycerides or free fatty acids in a subject in need thereof.
  15. Use of a compound according to any one of claims 1-2 or 9 for the manufacture of a medicament for preventing or treating diabetes caused by insulin resistance or impaired glucose tolerance or complications of diabetes said diabetes caused by insulin resistance or impaired glucose tolerance.
  16. Use of a compound according to any one of claims 1-2 or 9 for the manufacture of a medicament for reducing blood glucose, triglycerides or free fatty acids in a subject in need thereof.
EP98918108A 1997-12-02 1998-04-10 Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties Expired - Lifetime EP1036075B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US982911 1997-12-02
US08/982,911 US6313113B1 (en) 1997-04-15 1997-12-02 Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
PCT/US1998/007284 WO1998045291A1 (en) 1997-12-02 1998-04-10 Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties

Publications (2)

Publication Number Publication Date
EP1036075A1 EP1036075A1 (en) 2000-09-20
EP1036075B1 true EP1036075B1 (en) 2004-06-23

Family

ID=25529628

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98918108A Expired - Lifetime EP1036075B1 (en) 1997-12-02 1998-04-10 Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties

Country Status (6)

Country Link
EP (1) EP1036075B1 (en)
JP (1) JP2002510283A (en)
AT (1) ATE269862T1 (en)
AU (1) AU7109798A (en)
DE (1) DE69824756T2 (en)
WO (1) WO1998045291A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL197077B1 (en) 1998-12-01 2008-02-29 Reddys Lab Inc Dr New pharmaceutical composition and the process for its preparation
US6768008B2 (en) * 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
AU2001294673A1 (en) 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (en) * 1987-09-04 2000-05-11 Beecham Group Plc Substituted thiazolidinedione derivatives
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
TW363959B (en) * 1994-03-23 1999-07-11 Sankyo Co Thiazolidine and oxazolidine derivatives, their preparation and their medical use
RU2151145C1 (en) * 1994-04-11 2000-06-20 Санкио Компани Лимитед Intermediate compound for synthesis of heterocyclic compounds showing antidiabetic activity
TW399051B (en) * 1996-01-31 2000-07-21 Ssp Co Ltd A novel benzoazine thiazolidinedione derivative and pharmaceutical composition for reducing blood glucose
RU2200161C2 (en) * 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Novel derivatives of azolidinedione, method of their synthesis (variants), pharmaceutical compositions based on thereof, method of prophylaxis or treatment, method of glucose level decrease and intermediate compound

Also Published As

Publication number Publication date
WO1998045291A1 (en) 1998-10-15
DE69824756D1 (en) 2004-07-29
ATE269862T1 (en) 2004-07-15
DE69824756T2 (en) 2005-07-14
EP1036075A1 (en) 2000-09-20
AU7109798A (en) 1998-10-30
JP2002510283A (en) 2002-04-02

Similar Documents

Publication Publication Date Title
EP0971917B1 (en) Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties
EP0958296B1 (en) Heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6310069B1 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
EP0981526B1 (en) Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6313113B1 (en) Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5885997A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
WO1997041120A1 (en) Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
US6159966A (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
US5889025A (en) Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889032A (en) Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
EP1036075B1 (en) Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties
US6573268B1 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
EP0977753A1 (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension
USRE39266E1 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5919782A (en) Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6372750B2 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
EP0894089B1 (en) Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
MXPA98010782A (en) Heterociclic novedous compounds, process for their preparation and pharmaceutical compositions that contain them, and their use in the treatment of diabetes and related diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19991115;LT PAYMENT 19991115;LV PAYMENT 19991115;RO PAYMENT 19991115;SI PAYMENT 19991115

17Q First examination report despatched

Effective date: 20010903

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DR. REDDY'S LABORATORIES LTD.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV RO SI

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040623

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20040623

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040623

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040623

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040623

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69824756

Country of ref document: DE

Date of ref document: 20040729

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040923

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040923

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041004

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20040623

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050410

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050411

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050430

26N No opposition filed

Effective date: 20050324

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20060913

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20060915

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20060918

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20060921

Year of fee payment: 9

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20070410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20060925

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070430